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BK virus (BKV) is a member of the polyomavirus family that infects nearly the 
entire human population at an early age.  Following a subclinical primary infection, BKV 
is able to establish a persistent infection in the kidney and urinary tract.  Reactivation of 
BKV occurs in immunocompromised individuals and can lead to severe disease.  BKV-
associated diseases include polyomavirus nephropathy (PVN), a form of acute interstitial 
nephritis that afflicts up to 10% of renal transplant recipients, and hemorrhagic cystitis 
(HC), an infection of the bladder characterized by inflammation and hematuria that 
affects 10% of bone marrow transplant recipients.  PVN and HC are increasing in 
prevalence, likely due to the development of more potent immunosuppressive therapies.   
 To better understand which components of the immune system are important for 
regulating BKV infection, we began to examine the effect of cytokines on virus 
replication.  Interferon-gamma (IFN-γ) has a strong inhibitory effect on BKV 
transcription, gene expression, and replication, but does not affect the kinetics of the viral 
life cycle or trafficking of the virus to the nucleus.  IFN-γ treatment inhibited gene 
expression of three different BKV strains similarly, suggesting that regulation by this 
cytokine is relevant for all viral strains.  We have begun to further examine regulation of 
viral transcription by IFN-γ to identify the specific factors involved and investigate 
changes in viral chromatin structure.  In contrast to IFN-γ, TGF-β has an upregulatory 
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effect on BKV strain TU early promoter activity.  Three other strains examined, however, 
were either unaffected or downregulated by TGF-β treatment in a cell type-dependent 
manner.  The TGF-β response elements were mapped within the promoter of BKV TU.  
The viral strain- and cell type-dependent effects of TGF-β demonstrate the complex 
nature in which BKV is regulated by cytokine signaling.  
Finally, we have begun to investigate the inability of archetype BKV strains to 
replicate in tissue culture.  The linear structure of the non-coding control region (NCCR) 
distinguishes archetype from rearranged strains, which have duplications and deletions of 
NCCR sequences.  Exchanging the NCCRs of archetype and rearranged genomes restores 
archetype DNA replication but prevents rearranged DNA replication.  In addition, 
archetype DNA replication is observed in the presence of a TAg-expressing plasmid, 
suggesting that archetype viruses are limited in replication ability by their lower 
production of TAg.  Overall, our findings will help us to better understand BKV 
persistence in healthy individuals and reactivation in immunocompromised patients.  
 1
 
Viruses have long been studied for their ability to evade the host immune 
response and carry out their life cycles in the context of otherwise healthy individuals.  
For many viruses, this is primarily mediated by the production of viral gene products that 
mimic or block the mounting immune response.  Encoding such proteins in the viral 
genome, however, requires genetic space and therefore small viruses are limited in their 
capacity to make these factors.  BK virus (BKV) has a genome of only 5.2 kb and 
encodes only seven proteins, yet is able to establish a persistent infection in healthy 
individuals.  This chapter will provide detailed information on the molecular biology, 
immunology, and clinical aspects of BKV to provide the necessary background for the 
discussion of viral regulation by the host immune response and establishment of 




Genetics and Life Cycle of BK Virus 
BKV is a member of the family Polyomaviridae, a group of viruses characterized 
by similar genome structures, small nonenveloped virions, and the ability to induce 
tumors in cells that do not support productive infections (Imperiale and Major, 2007).  
There are two known human polyomaviruses, BKV and JC virus (JCV), however recent 
reports of viral sequences isolated from respiratory samples and skin cancer cells suggest 
the existence of three additional human polyomaviruses, WU, KI, and Merkel cell 
polyomavirus (Allander et al., 2007; Feng et al., 2008; Gaynor et al., 2007).  The 
polyomavirus family also includes the well-studied simian virus 40 (SV40) and mouse 
polyomavirus (Py); many details of BKV molecular biology are derived from what is 
known for these two viruses.  BKV is highly homologous to JCV and SV40, sharing 78 
to 90% homology at the amino acid level over the major viral proteins, and 75% and 69% 
DNA sequence homology throughout the genome, respectively (Cubitt, 2006; Imperiale, 
2001).  The polyomaviruses, however, are highly species specific and can only replicate 
efficiently in their natural host cells.  In addition, there is evidence suggesting the 
coevolution of these viruses with their hosts (Shadan and Villarreal, 1993).  Thus, SV40 
and Py can only provide limited information about the immune response to BKV or the 
dynamics of infection, transmission, and persistence in humans. 
BKV has a 40 to 45 nm icosahedral virion with a T = 7 lattice symmetry (Li et al., 
2003).  The virion is composed of 360 copies of VP1, arranged in 72 capsomeres, each of 
which contains five copies of VP1 and one copy of either VP2 or VP3 (Imperiale and 
Major, 2007).  The genome is a circular, double-stranded DNA approximately 5 kb in 
length, and is associated with cellular histones H2A, H2B, H3 and H4 both in the nucleus 
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of infected cells and in the virion (Meneguzzi et al., 1978).  This association with cellular 
histones leaves the virus vulnerable to regulation by host chromatin remodeling agents.  
The genome of BKV has three major regions: the non-coding control region, the 
early coding region, and the late coding region (Figure 1.1).  The non-coding control 
region (NCCR) contains a bidirectional promoter that drives the production of early 
region transcripts from one genomic strand and late region transcripts from the opposite 
strand.  In addition, the NCCR contains the origin of replication, three TAg binding 
motifs, and many cellular transcription factor binding sites.  The NCCR is the region of 
greatest variability between different isolates and thus distinguishes one “strain” of BKV 
from another (NCCR variants are henceforth termed strains in accordance with the 
literature).  The NCCR is also the region of least conservation among members of the 
polyomavirus family.  The early coding region contains the genes for large tumor antigen 
(TAg) and small tumor antigen (tAg), the transcripts of which are produced by alternative 
splicing of a common mRNA precursor.  There is now evidence of a third early protein in 
BKV called truncated T antigen (truncTAg; D. Das, A. Joseph, J. Abend, D. Campbell-
Cecen, and M. Imperiale, in preparation), that has a transcript structure similar to that of 
SV40 17kT and the T’ proteins of JCV (Trowbridge and Frisque, 1995; Zerrahn et al., 
1993).  The early region is highly conserved between the different BKV strains.  The late 
coding region contains the genes for viral capsid proteins VP1, VP2, and VP3, and the 
agnoprotein, the transcripts of which are also all produced by alternative splicing of a 
common mRNA precursor.  VP2 and VP3 are translated in the same reading frame using 
different start codons, such that VP3 is an N-terminal truncated form of VP2.  VP1 is 








Figure 1.1.  The genome of BKV.  This schematic shows the circular, double-stranded 
DNA genome of BKV.  The three major regions are shown as follows: the non-coding 
control region (NCCR, bottom section), the early coding region (left hemisphere), and the 
late coding region (right hemisphere).  Solid arrows represent transcripts that encode the 
viral proteins; dashed lines represent the differential splicing of the early coding region.  
Figure courtesy of Mengxi Jiang.     
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than that of VP2 and VP3.  The 5’ end of the transcript has another open reading frame 
from which agnoprotein is translated.  While the late proteins are highly conserved, there 
is a short region of variability (amino acids 61 to 83) within VP1 that is used to assign 
each strain of BKV to a particular subtype (I, II, III, IV; Jin, 1993; Jin et al., 1993).  
Subtype I viruses predominate in the human population, followed by subtype IV, while 
subtypes II and III are rare (Cubitt, 2006; Nukuzuma et al., 2006).  The functional 
relevance of BKV subtypes is not yet fully understood.  
The pathway for BKV entry and trafficking to the cell nucleus is not yet fully 
understood, but is somewhat distinct from that of JCV, SV40, and Py.  The receptor for 
BKV is either of the gangliosides GD1b and GT1b (Low et al., 2006) or an N-linked 
glycoprotein with an α(2,3)-linked sialic acid (Dugan et al., 2005); both reports note the 
importance of sialic acids in BKV receptor binding.  Upon engaging the receptor, the 
virus is internalized in a caveolae-dependent manner, similar to SV40 but distinct from 
JCV, which enters by clathrin-dependent endocytosis, and Py, which enters via a unique 
endocytic pathway (Anderson et al., 1996; Atwood, 2001; Eash et al., 2004; Pho et al., 
2000).  The subsequent steps of BKV trafficking to the nucleus are currently under 
investigation, but the pathway includes passage of the virus through the endoplasmic 
reticulum and involves both microtubules and actin filaments (Eash and Atwood, 2005; 
Low et al., 2006; Moriyama and Sorokin, 2008).  It is still unclear whether the partially 
disassembled virion or only the viral minichromosome is transported into the nucleus 
where replication occurs.   
The first event to follow delivery of the viral genome to the nucleus is 
transcription of the early region and subsequent production of TAg and tAg.  The 
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processes of transcription, translation, and DNA replication for BKV require the use of 
host cell enzymatic machinery, as the viral genome does not encode the proteins to 
accomplish these tasks.  TAg is arguably the most important of the viral proteins as it 
assists and regulates the host cell machinery in these processes, performing many 
functions that are critical to the viral life cycle (based on findings for SV40; Cole and 
Conzen, 2001; Kierstad and Pipas, 1996; Kim et al., 2001; Moens and Rekvig, 2001).  
Once translated in the cytoplasm, TAg translocates back to the nucleus by means of a 
highly conserved nuclear localization signal at the N-terminus.  TAg then interacts with 
the pRB family of proteins (pRB, p107, and p130), which releases the E2F transcription 
factor and drives the cell into S phase (Harris et al., 1996; Harris et al., 1998).  There are 
three known binding sites for TAg at the origin of replication which mediate several 
functions: 1) inhibition of early gene transcription by blocking RNA polymerase binding, 
2) initiation of viral genome replication by recruiting cellular proteins and acting as a 
helicase to facilitate the unwinding of the genome (Stahl et al., 1986; Stillman et al., 
1985), and 3) activation and promotion of late gene transcription by binding to the late 
promoter (Deyerle et al., 1989; Salzman et al., 1986).  TAg also binds and inactivates the 
tumor suppressor p53 to promote cell survival during infection (Harris et al., 1996; 
Shivakumar and Das, 1996).  Overall, TAg establishes a cellular environment that is 
supportive of viral replication.  Due to its importance to the viral life cycle, TAg 
expression may also be a key point of regulation by the host immune system.   
Small T antigen is somewhat viewed as an auxiliary TAg and is distributed 
throughout the cytoplasm and nucleus (Cole and Conzen, 2001).  It has been shown to 
enhance DNA replication (Cicala et al., 1994), mediate cell cycle progression (Howe et 
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al., 1998; Whalen et al., 1999), and aid in transformation of cells (Manfredi and Prives, 
1994).  A major function of tAg involves interaction with and inactivation of protein 
phosphatase 2A, which leads to cell proliferation and transformation; this is a unique 
function of tAg not shared by TAg (Skoczylas et al., 2004; Yang et al., 1991).  It appears, 
however, that tAg is dispensable in the context of lytic infection, based on the ability of 
BKV strain MM to mediate a productive infection in the absence of detectable tAg 
expression (Seif et al., 1979).  
The production of early proteins and the establishment of a suitable host cell 
environment promote replication of the viral genome.  BKV DNA replication begins at 
the origin of replication, proceeds bidirectionally using host DNA polymerase α-primase 
to prime the extension by DNA polymerase δ, and ends at the opposite side of the 
genome, where DNA ligase I replaces missing nucleotides and topoisomerase II mediates 
the separation of the daughter molecules (based on SV40 replication; reviewed in Kim et 
al., 2001).  Late gene transcription occurs concurrently and the capsid proteins (VP1, 
VP2, VP3) are translated and translocated back to the nucleus, the site of viral assembly.  
Lastly, agnoprotein is expressed at very late stages of lytic infection.  BKV agnoprotein is 
localized to the cytoplasm and perinuclear region, and interacts with cellular proteins of 
various molecular weights (Rinaldo et al., 1998).  Although the function is not well-
defined, it has been suggested that agnoprotein is important for virus assembly, 
maturation, and/or release (Rinaldo et al., 1998).  
Accumulation of late proteins and replicated genomes in the nucleus leads to 
virion assembly and release of progeny viral particles from the infected cell.  The details 
of assembly and release have not been determined.  This is the completion of the viral life 
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cycle in a permissive cell (Figure 1.2), resulting in production of mature, infectious 
particles and concluding with lysis of the infected cell or an undetermined mechanism of 
viral egress to release the progeny virions.  In addition, BKV can infect cells that are 
nonpermissive for productive infection, most notably rodent cells.  Nonpermissive 
infection results in early gene expression (TAg, tAg) but a failure to replicate viral DNA, 
most likely due to the inability of TAg to interact with and recruit cell replication 
machinery of another species.  The accumulation of TAg and tAg without progression to 
the late stages of infection results in oncogenic transformation.  
 
BK Virus Persistence and Associated Disease 
BKV was first discovered in 1971 in the urine of a renal transplant patient with 
ureteral stenosis (Gardner et al., 1971).  In the same year, JCV was isolated from human 
brain tissue from a patient with progressive multifocal leukoencephalopathy (PML) 
(Padgett et al., 1971).  From the beginning of their acknowledged existence, the human 
polyomaviruses were linked to significant disease.   
The route of transmission for BKV is not well-defined.  It is assumed that primary 
infection occurs either by the oral or respiratory route because of the widespread nature 
of BKV infection and the timing of seroconversion: 50% of children are seropositive by 
the age of 3 and 91% are seropositive by the age of 9 (Knowles et al., 2003).  The 
primary infection is typically subclinical, but has been associated with upper respiratory 
disease in children (Goudsmit et al., 1982).  Approaching adulthood, BKV 
seroprevalence declines slightly to approximately 81% for the general population 








Figure 1.2.  The life cycle of BKV.  Numbers indicate the steps of BKV infection and 
replication: 1) binding to receptor GD1b, GT1b, or sialic acid; 2) caveolae-dependent 
endocytosis; 3) trafficking, which involves microtubules and actin filaments; 4) passage 
through the endoplasmic reticulum; 5) delivery of genome to the nucleus; 6) early gene 
transcription and translation; 7) TAg returns to the nucleus to facilitate viral DNA 
replication and late gene transcription; 8) late gene transcription and translation; 9) capsid 
proteins return to the nucleus for assembly of progeny virions; 10) release of viral 
progeny by egress or cell lysis.  
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body; viral sequences have been reported in a variety of different cell types, including 
peripheral blood mononuclear cells (Chatterjee et al., 2000; Doerries et al., 1994), liver 
(Knepper and diMayorca, 1987), bone tissue (De Mattei et al., 1994), and brain (Elsner 
and Doerries, 1992).  Finally, BKV reaches the cells of the kidney and urinary tract, 
specifically proximal tubule epithelial cells and the urothelium (Chesters et al., 1983; 
Heritage et al., 1981), where it establishes a persistent, lifelong subclinical infection in 
healthy individuals.  It is reported that 50% of healthy native kidneys and 40% of ureters 
harbor BKV, with the highest levels (400 genome copies per 100,000 cells) in the renal 
medulla (Monini et al., 1995; Nickeleit et al., 2003).  Approximately 5% of healthy 
individuals actively excrete BKV in urine (viruria) at a rate of greater than 106 genome 
copies per ml (Zhong et al., 2007).  In addition, there is a high tendency of pregnant 
women to be viruric with no clinical outcome (Coleman et al., 1980; Markowitz et al., 
1991).  In healthy individuals, BKV has developed an effective means to coexist with the 
host, maintaining a subclinical infection that sporadically leads to viral excretion in the 
urine and potential transmission to new hosts.  
Certain conditions of the host, specifically immunosuppression, can allow BKV to 
‘reactivate’ from the persistent subclinical state to an active lytic infection, resulting in 
serious disease.  This is a feature common to polyomaviruses, as JCV, Py, and SV40 all 
undergo reactivation in immunocompromised hosts (Imperiale and Major, 2007).  Two 
major patient groups are highly susceptible to BKV reactivation: bone marrow transplant 
(BMT) recipients and kidney transplant (KT) recipients.  In BMT patients, BKV lytic 
infection occurs in the epithelial cells of the bladder or ureter, resulting in hemorrhagic 
cystitis (HC) characterized by viruria and hematuria.  HC is reported in 10 to 68% of 
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BMT patients, with 25% suffering from severe HC with heavy bleeding and intense pain 
(Arthur et al., 1986; Azzi et al., 1994; Bedi et al., 1995; Cotterill et al., 1992).  BKV-
associated HC occurs more than 10 days post-transplant (late-onset) and requires medical 
attention but is not usually life-threatening (Egli et al., 2007).  It has been suggested that 
HC is an immune reconstitution syndrome, in which the reactivation of BKV, and thus 
the presence of large amounts of viral antigens, sets off an excessive inflammatory 
response that causes damage to the urothelial cells (Hirsch, 2005).  
In KT recipients, reactivation of BKV is first evident by viral shedding in the 
urine, which occurs in 20 to 60% of patients.  About half of these patients then develop 
high levels of viremia (virus dissemination in the bloodstream; Brennan et al., 2005; 
Hirsch, 2005; Hirsch et al., 2002).  In these patients, BKV that established a subclinical 
infection in kidney epithelial cells has reactivated to a productive lytic infection in which 
viral progeny have spread to the surrounding cells of the medulla, renal cortex, and 
proximal tubules.  This condition is referred to as polyomavirus nephropathy (PVN) and 
the end stage involves necrosis of the tubules and denudation of the basement membrane 
(Nickeleit et al., 2003).  PVN is diagnosed primarily by examination of kidney biopsies 
for characteristics of virus-infected cells (enlarged nuclei, cytopathic effects), followed 
by immunohistochemistry to detect TAg expression (Drachenberg et al., 2005; Vats et al., 
2006).  In addition, PCR quantitation of viral genomes in biopsy samples and urine 
cytology to identify decoy cells (BKV-infected cells with characteristic morphology) are 
often employed (Singh et al., 2006).  If not controlled, the lytic infection will cause 
failure and destruction of the graft.  Approximately 1 to 10% of KT patients develop 
PVN, primarily during the first year post-transplantation, which coincides with the time 
 12
of highest immunosuppressive treatments.  Once diagnosed with PVN, 50 to 90% of 
patients progress to graft failure (Egli et al., 2007).  The incidence of PVN is increasing, 
most likely due to the combined effects of more potent immunosuppressive therapies, 
better methods of diagnosis, and the increasing number of KT performed every year.   
The treatment options for PVN are quite limited.  The most effective treatment to 
date is reduction of the immunosuppressive regimen, which allows the patient to mount 
an immune response and fight the infection.  There are currently no proven antiviral 
treatments for BKV, although some limited success has been seen with cidofovir and 
leflunomide (Bernhoff et al., 2008; Vats et al., 2006).  A third approach is nephrectomy 
to remove the transplanted kidney.  This has been shown to cause a rapid decrease in 
viral load, with a viral half-life as fast as one to two hours and greater than 99% turnover 
each day, compared to a viral half-life of six hours to 17 days resulting from a decrease in 
immunosuppression (Funk et al., 2006).  These findings suggest that the graft is the 
source of replicating BKV, not the kidney epithelial cells or urothelium of the recipient. 
There is no single risk factor shared by all patients that develop PVN; it is thought 
that BKV reactivation is prompted by a combination of factors from the virus, patient and 
graft (Comoli et al., 2006; Egli et al., 2007; Hirsch et al., 2006).  Specific individual risk 
factors include older age, male gender, seropositivity of the donor, seronegativity of the 
recipient, specific immunosuppressive drugs, HLA mismatches, and acute rejection 
episodes prior to development of PVN (Andrews et al., 1988; Bohl et al., 2005; Comoli et 
al., 2006; Egli et al., 2007; Mengel et al., 2003).  It is clear that an immunosuppressed 
state alone is not enough to cause PVN; not all KT patients suffer from PVN and there 
are only sporadic references to BKV reactivation and associated nephropathy in other 
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solid organ transplant patients or immunodeficiency syndromes, such as AIDS (Hirsch, 
2005; Pavlakis et al., 2006).   
Therefore, a primary topic addressed by investigators currently studying BKV 
reactivation is the identification of component(s) of the immune system that are critical 
for controlling BKV infections.  Further knowledge about the immune response to and 
control of BKV in healthy individuals may allow better treatment options for patients 
with PVN and HC.  Several clinical observations have been made about the immune 
response during BKV reactivation.  It is reported that 77% of patients are seropositive for 
BKV before KT (Hirsch et al., 2002) and that patients with detectable anti-BKV 
antibodies still progress to PVN (Comoli et al., 2004).  In fact, it seems that antibodies 
are more indicative of the viral load in a patient rather than protective against BKV 
infection, as high levels of antibodies in PVN patients correlate with high levels of 
viremia and low CD8+ T cell responses (Chen et al., 2006).  Thus, anti-BKV antibodies 
do not appear to play a major role in controlling infection and reactivation.  Furthermore, 
the cell-mediated cytotoxic immune response fails to eliminate all BKV-infected cells, 
allowing the establishment of a persistent infection in healthy individuals.  Cytokine-
producing T cells now show the most promise as key regulators of BKV reactivation: low 
levels of BKV-specific IFN-γ-producing T cells correlate with progression to PVN, while 
reconstitution of these cells correlates with resolution of PVN (Binggeli et al., 2007; 
Chen et al., 2006; Prosser et al., 2008).  Therefore, the fluid-borne effectors produced by 
T cells, such as cytokines, may be a critical means to control BKV replication and 
reactivation.  
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BKV NCCR and Transcriptional Regulation 
BKV strains can be divided into two major types, archetype and rearranged, based 
on the structure of the NCCR.  The archetype NCCR has a simple structure composed of 
five blocks of nucleotide sequences, designated O, P, Q, R, and S (Figure 1.3; Markowitz 
and Dynan, 1988; Rubinstein et al., 1987; Sundsfjord et al., 1994).  Rearranged strains 
have major structural changes in the NCCR, relative to the archetype, involving partial or 
whole duplications, deletions, or mutations of these blocks.  The O, P, Q, R, and S blocks 
were defined as sequences that appear to move together when rearrangements occur.  The 
O block is 142 bp long and highly conserved among all strains of BKV, likely because it 
contains the origin of replication, the TATA box, and the three TAg binding sites that are 
required to initiate replication.  The P block is 68 bp long and is present at least once in 
every strain isolated thus far, though it is frequently duplicated in part or in whole 
(Moens and Van Ghelue, 2005).  This region contains a cAMP response element (CRE) 
and proven binding sites for the transcription factors Sp1, AP-1, and NF-1.  The Q block 
is 39 bp long and contains proven binding sites for Sp1, NF-1, and NF-κB.  The R block 
is 63 bp long and has only been shown to contain an NF-1 binding site.  The S block, 
leading up to the start codon of agnoprotein, is 63 bp long and contains two proven NF-1 
sites, an estrogen response element, and a glucocorticoid and/or progesterone response 
element.  The Q and R blocks are frequently deleted from rearranged strains, while the S 
block is rarely altered (Cubitt, 2006; Johnsen et al., 1995; Moens and Rekvig, 2001; 
Moens and Van Ghelue, 2005). 
Rearrangements of the NCCR can add or remove transcription factor binding sites 











Figure 1.3.  The structure of archetype NCCR.  A schematic representation of the 
structure of archetype BKV NCCR.  Blocks of transcription factor binding sites are 
labeled by letter and length.  The locations of binding sites discussed in the text are 
shown.  Open green triangles represent TAg binding sites.  Open red circles represent 
NF-1 binding sites.  Arrows indicate the bidirectional nature of the promoter, initiating 
early gene transcription to the left and late gene transcription to the right.  Below is a 
schematic representation of the structure of a rearranged NCCR, BKV TU, which is used 
in most of our experiments.  CRE, cAMP response element; HRE, hormone response 
element.     
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sequences together, creating new binding sites at the junctions of blocks (Markowitz and 
Dynan, 1988; Markowitz et al., 1990).  Furthermore, BKV promoters may be regulated 
differently depending on the cell type infected.  It has been shown by DNase footprint 
analysis that different protein complexes bind to the NCCR during incubation with HeLa 
versus 293 cell extracts (Grinnell et al., 1988).  The observed binding patterns correlate 
with differences in promoter activity in these two cell lines, suggesting that replication 
capacity may also differ in a cell type-dependent manner. 
From the beginning, it was clear that there is a functional difference between 
rearranged and archetype NCCRs.  Archetype viruses are more efficient at transforming 
rodent cells but extremely inefficient at propagation in tissue culture, while rearranged 
BKV strains are highly adapted to growth in tissue culture but unable to efficiently 
transform cells (Watanabe and Yoshiike, 1982; Watanabe and Yoshiike, 1986).  Upon 
examination of the individual blocks, it was observed that an NCCR with a single P block 
was enough to initiate transcription, but that repetitions of the P block resulted in greater 
promoter activity (studies in HeLa cells; Chakraborty and Das, 1989; Deyerle and 
Subramani, 1988).  Insertion of P block fragments of a rearranged NCCR into an 
archetype NCCR resulted in enhanced transcriptional activity, indicating that it is not the 
presence of repressor elements in archetype strains, but instead the duplication of 
activator elements in rearranged strains that results in the elevated capacity to replicate 
(Markowitz et al., 1990).  By comparing the growth phenotypes of different BKV strains 
to their NCCR structures, it was noted specifically that the duplication of P blocks favors 
growth in HeLa cells (Markowitz and Dynan, 1988).  It was also shown that, in the 
presence of HeLa cell extracts and immunoaffinity purified TAg, a plasmid containing an 
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NCCR with a single P block replicated as well as one with three adjacent P blocks, and 
that mutation of the NF-1 and Sp1 binding sites within the P block had no effect on 
replication (Del Vecchio et al., 1989).  These results suggest that, in the presence of 
abundant TAg, the transcription and replication elements of the NCCR are separable; 
however, the functions in vivo are not, since replication requires efficient TAg 
expression, implying that the greater the activity of the early promoter, which drives the 
expression of TAg, the greater the replication capacity of the virus. 
It has long been thought that NCCR structure would play a role in BKV 
pathogenesis by giving rearranged viruses selective replication advantage over the 
archetype strains.  In many independent experiments, an archetype strain from a clinical 
isolate showed essentially no replication in tissue culture over the course of many weeks.  
If viral replication was detected, the NCCR structure of the progeny virus was 
rearranged, indicating that either a rearrangement event had occurred or the clinical 
sample used for infection contained an initially undetectable level of rearranged virus that 
eventually outgrew the archetype (Rinaldo et al., 2005; Rubinstein et al., 1991; 
Sundsfjord et al., 1994; Sundsfjord et al., 1990).  These studies have been performed in 
human umbilical vein endothelial (HUVEC-C), monkey kidney epithelial (Vero), and 
human embryonic kidney (HEK) cell lines.  A similar phenomenon is seen when 
archetype genomic DNA is transfected into cells: after extended incubation, the progeny 
virus, if produced, has NCCR rearrangements (Rinaldo et al., 2005; Rubinstein et al., 
1991).  This result directly demonstrates the evolution of a rearranged strain of BKV 
from an archetype genome. 
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Despite the evidence that rearranged strains are better at replicating in tissue 
culture, the vast majority of strains isolated from both healthy individuals and 
immunosuppressed patients have archetype NCCRs (Gosert et al., 2008; Markowitz et 
al., 1991; Negrini et al., 1991; Sharma et al., 2007; Sugimoto et al., 1989; Sundsfjord et 
al., 1999; Takasaka et al., 2004; ter Schegget et al., 1985).  It was recently reported, 
however, that rearranged strains are found more frequently in the blood of patients with 
PVN than in the urine, and that these strains attain 20-fold higher viral loads than 
archetype strains in the blood (Gosert et al., 2008).  In addition, kidney biopsies from 
PVN patients with rearranged strains had more evidence of inflammation than those with 
archetype strains.  This is the first report to link rearranged strains directly to more 
extensive viral replication and subsequent disease in patients.  Still, the authors could not 
identify any commonalities in the rearrangements that would implicate a specific NCCR 
element in pathogenesis.  The authors hypothesized that archetype strains are more 
successful in immunocompetent hosts because of their ability to remain relatively 
undetected by the immune system, by means of slower growth and lower levels of TAg 
(Gosert et al., 2008).  While the clinical relevance of NCCR rearrangements is not yet 
clear, many researchers are trying to show the association between transcription factor 
binding sites or NCCR structures with progression to disease.  For example, mutations in 
the Sp1 binding site at the junction of the Q and R blocks may be found more frequently 
in BMT patients with HC than those without, but the relevance and effect of the mutation 
on viral replication is not known (Priftakis et al., 2001). 
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Interferon-Gamma and Polyomaviruses 
Interferons are a class of cytokines widely known for their antiviral effects, and in 
fact were first discovered and named for their ability to “interfere” with viral infection 
(Isaacs and Lindenmann, 1957; Wheelock, 1965).  There are three classes of interferons, 
type I, type II, and type III, related by function and signaling pathways (reviewed in 
Biron and Sen, 2001; Pestka et al., 2004).  Type I interferons are a constantly growing 
class of molecules, which currently include IFN-α, IFN-β, IFN-ε, IFN-δ, IFN-κ, IFN-
τ, IFN-ω, and the interferon-like cytokine limitin.  Type III interferons, or IFN-λ, were 
only recently discovered and have two members, IL-28 and IL-29 (Ank et al., 2006).  
IFN-γ is the only member of the type II class, distinct from type I in that it is produced 
primarily by immune cells, mainly natural killer (NK) cells, T cells, antigen presenting 
cells (APCs), and B cells.  Type I interferons play a major role in innate immunity against 
viruses, as they are produced by almost all cell types and are quickly induced by viral 
components, such as double-stranded RNA.  In contrast, IFN-γ can be produced as an 
innate immune mediator by NK cells, or as an adaptive immune mediator when produced 
by T cells, B cells, and APCs.  Viral antigens must be presented to T cells in the proper 
MHC context to activate IFN-γ expression.  IFN-γ is primarily associated with the T 
helper 1 (Th1) phenotype: production is enhanced by IL-2, IL-1, estrogen, IL-18, IL-12, 
and IFN-γ itself, but inhibited by glucocorticoids, TGF-β and cytokines associated with 
the Th2 phenotype (Biron and Sen, 2001).  
IFN-γ is a 21 kDa cytokine expressed as a homodimer.  The receptor is present on 
the surface of almost all nucleated cells and is composed of two heterodimers of IFNGR1 
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and IFNGR2 molecules, distinct from the IFN-α/β receptor.  Janus kinase 1 (JAK1) is 
bound to the cytoplasmic tail of IFNGR1 while JAK2 is bound to IFNGR2, and upon 
IFN-γ binding, these two kinases are phosphorylated.  JAK1 and JAK2 then 
phosphorylate the cytoplasmic domain of IFNGR1, which allows binding of signal 
transducer and activator of transcription 1 (STAT1) to the receptor.  STAT1 molecules 
are then phosphorylated which results in their dimerization; homodimers of STAT1, 
known as the gamma-activated factor (GAF), translocate to the nucleus and bind gamma-
activated sequences (GAS) to promote transcription of IFN-γ responsive genes.  
Crosstalk between the IFN-α/β and the IFN-γ signaling cascades can result from IFN-
α/β-stimulated activation of GAF, although primarily the type I interferons signal 
through the complex of STAT1, STAT2, and interferon regulatory factor 9 (IRF-9), 
which binds the interferon-stimulated response element (ISRE) in promoters.  
Furthermore, in certain situations GAF can complex with IRF-9 and mediate signaling 
through ISREs (reviewed in Pestka et al., 2004; van Boxel-Dezaire and Stark, 2007). 
The effects of IFN-γ signaling on a cell are far-reaching and diverse (Biron and 
Sen, 2007; Sen, 2001; van Boxel-Dezaire and Stark, 2007).  First, IFN-γ has an important 
immunomodulatory role which it mediates by activating monocytes to produce nitric 
oxide synthase 2 (iNOS, important for eliminating bacteria), inducing expression of 
chemokines to recruit and activate immune cells, activating NK cell cytotoxicity, 
increasing MHC class I and II expression, promoting differentiation of CD4+ T cells, and 
promoting immunoglobulin class switching.  In nonimmune cells, interferon signaling is 
mostly directed at establishing an antiviral state.  Among the genes activated are protein 
kinase R (PKR), which phosphorylates eukaryotic initiation factor 2 (eIF-2α) to inhibit 
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translation; 2’-5’ oligoadenylate synthetase, which activates RNaseL to nonspecifically 
degrade mRNA; adenosine deaminase, which introduces adenosine to inosine changes in 
transcripts to affect protein expression and function; and IRFs, which potentiate the 
signaling cascade by mediating interferon synthesis and interferon responsive gene 
regulation.  The overall effect on the cell is anti-proliferative and pro-apoptotic.  
Transcription factors other than STAT1 known to be activated during IFN-γ signaling 
include STAT3, AP-1, USF-1, NF-κB, IRF-1, IRF-8, ATF-2, GATA-1, CREB, and PU.1, 
as well as C-EBP-β and CIITA, which are newly synthesized in response to signaling and 
mediate the second wave of the cascade (van Boxel-Dezaire and Stark, 2007).  The 
crosstalk between the type I and type II interferon pathways creates difficulty in defining 
genes as being specifically regulated by IFN-α/β or IFN-γ.  Several studies have 
examined the differential effects of interferon signaling by microarray in various cell 
types, including human lung carcinoma (Sanda et al., 2006; Tan et al., 2005) and human 
fibrosarcoma (Der et al., 1998) cell lines.     
Many viruses have developed methods to overcome the interferon response by 
blocking interferon synthesis or interferon-mediated signaling and effectors, or even by 
expressing interferon receptor decoys (Biron and Sen, 2007; Sen, 2001).  Despite the 
small genome size, and thus the limited ability to encode specific inhibitor and decoy 
proteins, there are several reports that polyomaviruses can resist the antiviral effects of 
interferons.  SV40 TAg can inhibit PKR-mediated deactivation of eIF-2α, most likely by 
stimulating a cellular phosphatase to dephosphorylate eIF-2α (Swaminathan et al., 1996).  
Py has been shown to specifically inhibit IFN-β-stimulated gene expression by blocking 
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the activation of the STAT1/STAT2/IRF-9 complex through the interaction of TAg with 
JAK1 (Weihua et al., 1998).   
The regulation of human polyomaviruses by interferons is currently being 
investigated.  With the increasing popularity of microarray studies, two groups have 
separately examined changes induced by JCV infection of cultured cells.  The first study 
analyzed the effect of infection with JCV/SV40 chimeric viruses, containing JCV coding 
regions and JCV/SV40 hybrid NCCRs, on human fetal astrocyte cultures.  During 
infection, there was a strong upregulation in cell cycle genes, as anticipated, but 
surprisingly no effect on interferon-responsive genes and very little effect on genes 
relating to the immune response in general (Radhakrishnan et al., 2003).  In contrast, the 
second study reported that transfection of JCV genomic DNA into primary human fetal 
glial cells stimulated a variety of immune response genes, in particular interferon-
stimulated genes (Verma et al., 2006).  The upregulation of several factors was confirmed 
during JCV infection and, in a follow-up study, the authors reported that the induction of 
the interferon response required active JCV replication, not just the presence of viral 
products or DNA (Co et al., 2007).  In addition, they noted an inhibition of JCV 
replication by IFN-α/β treatment at late time points during infection (Co et al., 2007).  
There has only been one microarray study published analyzing the effect of BKV 
infection on immortalized human umbilical vein endothelial cells.  As expected, the 
authors report the upregulation of cell cycle-related genes at various times after infection; 
however, they saw no induction of interferon transcripts, the upregulation of only two 
interferon-inducible genes, and the downregulation of several genes involved in antiviral 
defense (Grinde et al., 2007).   These results indicate that BKV may have the ability to 
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infect cells in such a way as to avoid detection by the innate intracellular immune 
response.  
Transforming Growth Factor-Beta 
Members of the TGF-β family of cytokines are secreted proteins that share 
sequence and structural features and have similar signaling cascades within the cell.  This 
family includes the bone morphogenic proteins (BMPs), which are important during 
development; activins, which regulate growth and differentiation; and the TGF-β 
isoforms, TGF-β1, TGF-β2, and TGF-β3, which have similar functions in the adaptive 
immune response.  The TGF-β family members are expressed in most cell types, 
although the effect on TGF-β signaling can be cell type-dependent.  This section will 
focus specifically on the details of TGF-β1 signaling and regulation.  
The precursor of TGF-β is a prepro-peptide that contains a signal peptide for 
secretion, an immature propeptide called the latency associated protein (LAP) that is 
removed by proteolytic cleavage in the Golgi (Dubois et al., 1995), and the mature TGF-
β protein, a 25 kDa dimer (Feng and Derynck, 2005; Li et al., 2006; Rahimi and Leof, 
2007).  TGF-β can be secreted in two different forms: the small latent complex (SLC), a 
homodimer of mature TGF-β associated with a homodimer of LAP, or the large latent 
complex (LLC), the SLC in association with latent-TGF-β binding protein (Annes et al., 
2003).  The liberation of mature TGF-β from the latency proteins in vivo is not fully 
understood, but can be mediated by thrombospondin-1, matrix metalloproteinases, 
integrins and reactive oxygen species, among others (Li et al., 2006; Yang et al., 2007).  
The mature TGF-β binds to a cell surface receptor that is composed of two type I 
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receptors (TβRI) and two type II receptors (TβRII).  Upon ligand binding, the receptor 
complex autophosphorylates: first TβRII phosphorylates TβRI and then TβRI itself 
undergoes autophosphorylation.  Finally, TβRI phosphorylates Smad proteins in the 
cytoplasm (Derynck and Zhang, 2003; Shi and Massague, 2003).   
There are eight Smad proteins expressed in mammalian cells, falling into three 
classes: the receptor Smads (R-Smad, Smad1, 2, 3, 5, 8), the common Smad (Co-Smad, 
Smad4), and the inhibitory Smads (I-Smad, Smad6, 7).  R-Smads (Smad2 and 3 in the 
case of TGF-β1) are phosphorylated by TβRI, form a complex of two R-Smads and one 
Co-Smad, and then translocate to the nucleus to act as transcription factors.  This 
Smad2/3/4 complex binds to (5’  CAGAC  3’) sequences in promoters, also known as the 
Smad binding element (SBE; Shi et al., 1998; Zawel et al., 1998).  Smad proteins by 
themselves have only weak DNA binding activity unless multiple SBEs are present (Shi 
et al., 1998; Zawel et al., 1998).  More commonly, the complex interacts with other 
transcription factors that have more specific or higher affinity DNA binding abilities to 
regulate gene expression.  These factors must have the ability to interact with Smad 
proteins and have a DNA binding site nearby to the SBE (Derynck and Zhang, 2003; Shi 
and Massague, 2003).  Co-Smad interactions help to stabilize the R-Smad interactions 
with other transcription factors.  I-Smads are negative regulators of Smad signaling: 
Smad6 competes with Smad4 for binding to R-Smads and forms inactive complexes 
(Hata et al., 1998), while Smad7 competes with R-Smads for binding to the activated 
receptors (Hayashi et al., 1997; Nakao et al., 1997).  Smad7 is induced by IFN-γ 
signaling through the JAK/STAT pathway and by NF-κB signaling in response to 
inflammatory cytokines (Bitzer et al., 2000; Giannopoulou et al., 2006; Ulloa et al., 
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1999).  There is an extensive list of transcriptional coactivators and corepressors that 
interact with Smad complexes and mediate TGF-β-responsive gene regulation, including 
AP-1, FAST proteins, NF-κB, p300/CBP, P/CAF, Sp1, and ZEB proteins (Brown et al., 
2007; Feng and Derynck, 2005). 
The effects of TGF-β family members vary depending on the cell type, but overall 
these cytokines can regulate proliferation, differentiation, migration, and cell survival 
during development, carcinogenesis, fibrosis, wound healing and immune responses 
(Blobe et al., 2000; Li et al., 2006).  In immune cells, TGF-β-mediated signaling 
generally results in inhibition of growth and differentiation, resulting in tolerance and 
immunosuppressive effects (Li et al., 2006).  Similarly, TGF-β signaling in epithelial 
cells usually results in growth arrest and apoptosis; in fibroblasts, however, TGF-β 
promotes proliferation and activation (Rahimi and Leof, 2007).  Several reports have 
shown that various immunosuppressive therapies commonly used in both solid organ 
transplant and BMT patients cause an increase in TGF-β expression, particularly in renal 
epithelial cells (Khanna et al., 1999a; Khanna et al., 1999b; McMorrow et al., 2005; 
Shihab et al., 1996); these observations complement the overall immunosuppressive 
effects of TGF-β.    
There are numerous reports of viruses that induce TGF-β expression, including 
cytomegalovirus, hepatitis B virus, hepatitis C virus, and HIV; the immunosuppressive 
effects of TGF-β have obvious benefits for the virus during infection (Li et al., 2006; 
Reed, 1999).  However, there are also several reports of viruses that are regulated by the 
signaling events of the TGF-β pathway.  TGF-β treatment was shown to inhibit viral 
RNA replication and protein expression from a hepatitis C virus replicon (Murata et al., 
 26
2005).  Overexpression of Smad3 and Smad4 proteins regulates the activity of HIV-1 
LTR in astrocytes (Coyle-Rink et al., 2002).  TGF-β1 can induce the reactivation of lytic 
EBV replication from latently-infected epithelial cells (Fukuda et al., 2001) and B cells 
(di Renzo et al., 1994; Fahmi et al., 2000).  In addition, JCV early and late promoter 
activities are upregulated by Smad3 and Smad4 overexpression (Enam et al., 2004), and 
treatment of JCV-infected astrocytes with TGF-β stimulates viral replication 
(Ravichandran et al., 2007).  Therefore, TGF-β expression and regulation is highly 
relevant for viral infections. 
Summary and Chapter Outline 
The human polyomavirus BKV is able to establish a persistent, subclinical 
infection in nearly the entire population, which demonstrates its ability to at least partially 
evade the cytotoxic immune response.  In immunosuppressed patients, particularly KT 
and BMT recipients, BKV can reactivate to a productive lytic infection, suggesting that 
the loss of certain immune components in conjunction with other factors alleviates 
repression of viral infection.  We hypothesized that soluble immune factors, such as 
cytokines, may play an important role in regulating BKV.  Therefore, the decrease in 
lymphocyte proliferation and activation during immunosuppression may promote BKV 
reactivation, as a result of reduced cytokine expression.   
Previously, our lab has developed a cell culture system for the study of BKV 
infection in the natural host cell for reactivation, renal proximal tubule epithelial cells 
(Low et al., 2004).  In this system, the absence of immune surveillance mimics the 
environment of an immunosuppressed patient and may allow the examination of 
cytokine-mediated effects on BKV in a highly relevant host cell.  In Chapter II, we 
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describe the inhibitory effect of IFN-γ on BKV replication and demonstrate that the 
primary level of regulation is early gene transcription.  In Chapter III, we report the 
differential effects of TGF-β on early promoter activity.  In contrast to IFN-γ-mediated 
regulation, which is similar for three rearranged strains of BKV examined, TGF-β-
mediated effects vary, depending on the strain of virus and the cell type.  In Chapter IV, 
we begin a deeper investigation to analyze the mechanism of BKV promoter regulation, 
specifically chromatin remodeling, in the context of IFN-γ restriction of replication and 
during infection with archetype virus.  In Chapter V, we will discuss the relevance of our 
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  Polyomavirus nephropathy (PVN) results in renal dysfunction and graft loss in up 
to 10% of all kidney transplant recipients (Hirsch et al., 2005).  It is widely accepted that 
BK virus (BKV) is the etiological agent responsible for the majority of cases of PVN, 
which are typically diagnosed within the first year after transplantation (Hirsch et al., 
2002; Hirsch and Steiger, 2003).  PVN is characterized by the lytic, destructive 
replication of BKV in proximal tubule epithelial cells in the transplanted kidney and is 
normally diagnosed by renal biopsy to assess histological effects of infection, PCR to 
determine viral presence and loads in the urine and blood, and the detection of decoy 
cells, which are cells with distinct intranuclear inclusion bodies that are shed during 
active BKV replication, in the urine (Drachenberg et al., 2005; Hirsch, 2005; Nickeleit et 
al., 2003).  Since there are currently no effective antiviral treatments for BKV infection, 
the most common approach used to control PVN is to decrease the patient’s 
immunosuppressive regimen.  However, such an approach increases the risk of graft 
rejection and thus is not an appealing strategy.  The prevalence of PVN is increasing with 
the advent of new, more powerful immunosuppressive therapies, making it a growing 
concern for the transplant community.
CHAPTER II  
INHIBITORY EFFECT OF INTERFERON-GAMMA ON BK VIRUS GENE 
EXPRESSION AND REPLICATION 
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The human polyomavirus BKV was first isolated in 1971 in the urine of a renal 
transplant recipient (Gardner et al., 1971).  BKV virions are small (40 to 45 nm in 
diameter), non-enveloped, icosahedral, and contain a circular, double-stranded DNA 
genome of approximately 5.2 kb (Moens and Rekvig, 2001), which is associated with 
cellular histones to form a chromatin-like structure (Meneguzzi et al., 1978).  The 
genome encodes only six known proteins: the early proteins, large tumor antigen (TAg) 
and small tumor antigen (tAg), and the late proteins, VP1, VP2, VP3, and agnoprotein.  
BKV infects nearly the entire population, with seroprevalence reaching 60 to 80% by the 
age of 10 (Knowles, 2001).  BKV is thought to be contracted by respiratory transmission 
and the primary infection is typically subclinical.  Following the initial infection, BKV 
spreads to other cells of the body, most notably peripheral blood mononuclear cells 
(Doerries et al., 1994) and cells of the kidney and urinary tract (Chesters et al., 1983; 
Heritage et al., 1981; Shinohara et al., 1993), in which the virus establishes a persistent, 
subclinical infection.  It is from these sites in immunocompromised patients that BKV 
reactivates to a lytic infection, resulting in BKV-associated diseases such as PVN.  
Previously, we described an in vitro system that allows the study of BKV lytic 
infection of primary human proximal tubule epithelial cells (Low et al., 2004).  The 
functions of proximal tubule cells in the kidney include facilitating the recovery of blood 
products, maintenance of blood pressure and volume, and production and release of 
cytokines and chemokines to communicate with the host immune system (Briggs et al., 
2001; Daha and van Kooten, 2000).  Proximal tubule cells remain in a differentiated state 
for up to six passages in tissue culture (Humes et al., 2002) and thus provide an 
environment similar to that which BKV encounters in an immunocompromised host.  By 
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introducing individual elements of the immune system to this model, we can begin to 
determine which components regulate BKV replication.  In part because proximal tubule 
epithelial cells are known to interact both with neighboring cells and with the immune 
system through the production of cytokines and chemokines, namely IL-6, IL-8, IL-15, 
TNF-α, MCP-1, RANTES, and TGF-β (Daha and van Kooten, 2000), we began to 
investigate the role of cytokines in mediating regulation of BKV replication.  
Our interest in the effects of cytokines on BKV replication was initiated by 
clinical reports and observations that argued for the importance of the cell-mediated 
immune response, as opposed to other arms of the immune system, in controlling BKV 
persistent infection.  First, it has been demonstrated that up to 90% of the adult 
population has BKV-specific antibodies (Knowles, 2001) and patients with levels of anti-
BKV antibodies similar to those of healthy individuals still develop PVN (Hariharan et 
al., 2005; Hirsch et al., 2002).  Several reports detail the activation of the humoral 
immune response in patients with PVN, although antibody levels are shown to increase 
only after the stabilization of renal function and a decrease in viral load (Chen et al., 
2006; Comoli et al., 2004; Hariharan et al., 2005).  Furthermore, high titers of BKV-
specific antibodies in the donor correlate well with the incidence of BKV reactivation in 
the recipient (Bohl et al., 2005).  These findings suggest that the presence of BKV-
specific antibodies does not prevent reactivation and development of PVN, although they 
may be effective at controlling viremia (Chen et al., 2006).  In addition, the failure of the 
cytotoxic T lymphocyte (CTL) response to eliminate all cells harboring BKV, as 
demonstrated by the well-documented periodic shedding of virus in immunocompetent 
individuals, indicates that another facet of the immune system plays a role in controlling 
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persistent infection.  There are several studies demonstrating the correlation of low levels 
of BKV-specific interferon-gamma (IFN-γ)-producing cells and the development of 
viremia and PVN (Chen et al., 2006; Comoli et al., 2004).  Furthermore, others have 
reported the inhibitory effect of IFN-γ on the promoters of SV40, a related polyomavirus, 
and human cytomegalovirus, which lacks structural relatedness to BKV but has similar 
epidemiological features, such as latency in the kidney and reactivation upon 
immunosuppression (Harms and Splitter, 1995; Qin et al., 1997; Ritter et al., 2000).  
These findings prompted us to investigate the potential regulation of BKV replication by 
IFN-γ. 
 IFN-γ is the sole member of the type II family of interferons and is a secreted 
glycoprotein of ~25 kDa produced primarily by natural killer cells during the innate 
immune response and specific antigen activated-T lymphocytes during the adaptive 
immune response (Pestka et al., 2004; Schroder et al., 2004).  Activation of the IFN-
γ cascade within a cell is initiated by the binding of IFN-γ to the cell surface receptor and 
subsequent activation of the JAK-STAT signaling pathway.  JAK1 and JAK2 kinases, 
which are associated with the two chains of the IFN-γ receptor, IFNGR1 and IFNGR2, 
respectively, become phosphorylated upon IFN-γ binding.  As a result, STAT1 
homodimers are phosphorylated and subsequently translocated to the nucleus, where they 
act as transcription factors to mediate regulation of IFN-γ responsive genes (Pestka et al., 
2004; Schroder et al., 2004).  IFN-γ was first discovered by its antiviral activity 
(Wheelock, 1965) and remains widely known as a potent antiviral cytokine.  Among the 
genes up-regulated by the IFN-γ signaling cascade are protein kinase R, which inhibits 
cellular translation by phosphorylating and inactivating eukaryotic initiation factor-2; 2'-
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5' oligoadenylate synthetase, which activates RNaseL to non-specifically degrade mRNA 
transcripts and inhibit gene expression; and interferon regulatory factor 1 (IRF-1), which 
up-regulates production of caspase 1 and promotes apoptosis of the cell.  IFN-γ also plays 
a major role in the activation and recruitment of immune cells and up-regulates the 
expression of MHC class I and II molecules on the cell surface.  More generally, IFN-
γ significantly (by at least two-fold) affects the expression of more than 100 genes in 
mammalian cells (Der et al., 1998).  In addition, other genes may be regulated indirectly 
by a group of IFN-γ-responsive transcription factors that perpetuate the signaling 
cascade.  These transcription factors may also act on viral promoters to inhibit viral gene 
expression and replication.  
 In this report, we characterize the specific inhibitory effect of IFN-γ on BKV gene 
expression and replication during lytic infection of proximal tubule cells.  We were 
interested in determining the points at which the viral life cycle is affected and the 
conditions in which IFN-γ has the strongest inhibitory effect on viral replication.  IFN-γ 
inhibited BKV gene expression, both at the level of transcription and translation, and 
reduced the level of viral progeny produced during lytic infection.  These results are 
important for understanding the host immune response to BKV and, more specifically, 
the role of cytokines in regulating BKV replication and infection.  
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Materials and Methods 
Cell culture.  Primary human renal proximal tubule epithelial cells (RPTE cells, 
Cambrex) were maintained for up to six passages in renal epithelial cell basal medium 
(REBM, Cambrex) supplemented with human epidermal growth factor, fetal bovine 
serum, hydrocortisone, epinephrine, insulin, triiodothyronine, transferrin, and GA-1000 
as indicated for renal epithelial cell growth medium (REGM, supplements obtained as 
REGM SingleQuots, Cambrex).  RPTE cells were grown at 37°C with 5% CO2 in a 
humidified incubator. 
Viruses.  The genome of the TU strain of BKV was cloned into the EcoRI site of pGEM-
7Zf(-).  Genomes of the Dunlop and Proto-2 strains of BKV were cloned into the BamHI 
site of pBR322 (gift of P. M. Howley).  BKV stocks were prepared from these genomic 
clones:  4 μg plasmid DNA was digested with restriction enzymes (EcoRI for BKV(TU), 
BamHI for BKV(Dunlop, Proto-2)), recircularized with T4 DNA ligase and phenol-
chloroform extracted, and the resulting DNA was transfected into one T75 flask of 60% 
confluent RPTE cells (~ 4 x 106 cells) using Effectene (Qiagen).  After three weeks, cells 
and supernatants were collected and viral lysates were prepared by three freeze (-80°C) / 
thaw (37°C) cycles.  The resulting lysates were used to infect four T75 flasks of 70% 
confluent RPTE cells and after three weeks, viral lysates were prepared as above.  The 
resulting viral stocks were titrated by fluorescent focus assay and the integrity of the non-
coding control region (NCCR) was confirmed by sequencing of PCR products.   
Cytokines and chemokines.  Recombinant human IFN-γ, IL-6, IL-8, MCP-1, RANTES, 
and TNF-α were purchased from PeproTech, Inc. and reconstituted according to 
manufacturer’s recommendations.  Recombinant human IFN-α was purchased from 
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Sigma and supplied as a solution in PBS.  The doses used to treat BKV-infected RPTE 
cells were as follows: IL-6, IL-8, MCP-1, TNF-α were used at 100 ng/ml, RANTES was 
used at 300 ng/ml, IFN-α was used at 50 or 250 U/ml, and IFN-γ was used primarily at 
50 or 250 U/ml, with the exception of the dose response experiment in which six five-
fold dilutions were used, starting from 1250 U/ml.     
Infections.  Unless otherwise stated, 70% confluent RPTE cells were infected with the 
TU strain of BKV at an MOI of 0.5, incubating for one hour at 37°C.  Viral lysate used 
for the infection was replaced with fresh media (REGM) and cytokines were added three 
to six hours post-infection.   
Western blotting.  Unless otherwise stated, total cell protein was harvested at four days 
post-infection using E1A lysis buffer (Harlow et al., 1986) supplemented with 5 μg /ml 
PMSF, 5 μg /ml aprotinin, 5 μg /ml leupeptin, 0.05 M sodium fluoride, and 0.2 mM 
sodium orthovanadate.  The Bio-Rad protein assay was used to determine the protein 
concentration of each lysate and 8 μg of protein were electrophoresed on an 8% SDS-
polyacrylamide gel.  Proteins were transferred to nitrocellulose membrane in 1x Towbin 
buffer (25 mM Tris, 192 mM glycine, 20% methanol) for 12 to 14 hours at 60 volts 
(constant) and 4°C.  The following primary antibodies were diluted in PBS containing 
0.1% Tween (PBS-T) and 5% nonfat dry milk: pAb416 (Harlow et al., 1981) for 
detection of TAg expression, P5G6 (gift of D. Galloway) for detection of VP1 
expression, and Ab8245 (Abcam) for detection of glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) expression as a loading control.  Blots were washed in PBS-T, 
probed with horseradish peroxidase-conjugated anti-mouse IgG secondary antibody 
(Sigma), and developed using ECL+ reagent (Amersham) and exposure to film.      
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Fluorescent Focus Assay (FFA).  Viral lysates were harvested at T = 0 (after one hour 
absorption at 37°C) and four days post-infection (or at T = 0 and 1, 2, 3, 4, and 6 days 
post-infection for the viral growth curve) by collecting and preparing infected cells and 
supernatants by three freeze/thaw cycles, as described above.  Seventy percent confluent 
RPTE cells in 24-well plates were infected with 10-fold dilutions of viral lysates for four 
days at 37°C.  Cells were fixed with 50% methanol/50% acetone for 10 min at room 
temperature, air dried for 15 min, wrapped in parafilm and stored overnight at -20°C, as 
an antigen retrieval step.  Plates were thawed briefly at room temperature, rehydrated 
with PBS, and incubated for one hour at 37°C with pAb416 in PBS, followed by FITC-
conjugated anti-mouse IgG secondary antibody (Sigma) in PBS with 0.005% Evans Blue 
stain.  Titer was determined by counting five random fields in at least three replicate 
wells and is expressed as infectious units per ml (IU/ml).  Statistical significance was 
determined using a two-tailed Student’s t test assuming unequal variance and P values 
< 0.05 were considered significant.      
RNA extraction and cDNA synthesis.  Total cell RNA was harvested at two or four 
days post-infection using TRIzol reagent (Invitrogen) according to manufacturer’s 
instructions.  RNA samples were treated with DNaseI (Promega) to reduce contaminating 
DNA and the integrity of the RNA was confirmed by electrophoresis on an agarose gel.  
To generate cDNA, a reverse transcription reaction was performed using 1 μg RNA as 
template and the iScript cDNA Synthesis Kit (Bio-Rad), according to manufacturer’s 
instructions.    
Real Time PCR: Taqman Assay.  Primers and probes were designed using Primer3 
software (Rozen and Skaletsky, 2000) to amplify 90- and 105-base pair fragments of the 
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TAg and GAPDH genes, respectively; sequences are shown in Table 1.  Primers were 
synthesized by Invitrogen and probes, tagged with 6-fluorescein (FAM) as the reporter 
dye at the 5' end and TAMRA-Sp as the quencher dye at the 3' end, were synthesized by 
Integrated DNA Technologies, Inc. (IDT).  Reactions were performed in a total volume 
of 25 μl using TaqMan Universal PCR 2x master mix (Applied Biosystems), 2.5 μl 
cDNA template, 500 nM of each primer, and 200 nM probe.  Amplification was 
performed in 96-well PCR plates (Bio-Rad) using the iCycler iQ5 Real Time Detection 
System (Bio-Rad) with the following PCR program:  2 min at 50°C; 10 min at 95°C; 40 
cycles of denaturation at 95°C for 15 sec and annealing and extension at 56°C for 1 min.  
Results are presented as the fold change in TAg transcript levels, with the levels in 
samples treated with 250 U/ml IFN-γ arbitrarily set to one.  Results were normalized to 
the levels of GAPDH transcripts present using the 2-ΔΔC(T) (Livak) method (Livak and 
Schmittgen, 2001).  Statistical significance was determined using a two-tailed Student’s t 
test assuming unequal variance and P values < 0.05 were considered significant.   





Gene  Sequence (5' to 3') 
TAg Forward Primer AAAAATGGAGCAGGATGTAAAGGT 
 Reverse Primer TCTTCTGTTCCATAGGTTGGCA 
 Probe AGCTACTCCAGGTTCCAAAATCAGGCTGA 
GAPDH Forward Primer GCCTCAAGATCATCAGCAAT 
 Reverse Primer CTGTGGTCATGAGTCCTTCC 




















Table 1. Sequences of primers and probes used in Taqman Real Time PCR assays. 
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Results 
IFN-γ inhibits the expression of viral genes during infection with BKV.  To begin our 
investigation of the role of cytokines and chemokines in regulating BKV infection, we 
examined the effect of several molecules on viral gene expression during infection of 
RPTE cells.  The cytokines and chemokines used in this experiment were chosen for their 
well-known antiviral effects (IFN-α and IFN-γ) or because they are produced by 
proximal tubule epithelial cells following injury or stimulation (Daha and van Kooten, 
2000).  RPTE cells were infected with BKV, treated with IFN-γ, IFN-α, IL-6, IL-8, 
MCP-1, RANTES, or TNF-α, and total cell protein was harvested at four days post-
infection.  As a control, the ability of each cytokine to stimulate RPTE cells was analyzed 
by Western blot: phosphorylation of STAT1 was observed for IFN-γ and IFN-α, while 
phosphorylation of ERK1/2 was observed for IL-6, IL-8, MCP-1, and TNF-α; results for 
RANTES were inconclusive (data not shown).  Western blot analysis of lysates probing 
for the viral proteins TAg, representing early gene expression, and VP1, representing late 
gene expression, revealed that only IFN-γ had a significant effect on viral gene 
expression (Figure 2.1A).  Similar levels of GAPDH, a cellular housekeeping gene, were 
detected in all samples, showing that the inhibitory effect on viral gene expression was 
specific and could not be attributed to the known non-specific cellular effects of IFN-γ, 
namely the induction of anti-proliferative and pro-apoptotic pathways (Figure 2.1A).  
Comparable results were obtained when samples were normalized to the total number of 
cells per lysate (data not shown). Although IFN-α and IL-6 both appeared to have a slight 







Figure 2.1.  Dose-dependent IFN-γ inhibition of BKV gene expression.  RPTE cells 
were infected with the TU strain of BKV at an MOI of 0.5 and treated with cytokines at 
three to six hours post-infection, and total cell protein was harvested at four days post-
infection.  Samples were analyzed by Western blotting, probing for TAg, VP1, and 
GAPDH.  A) Infected cells were treated with 50 or 250 U/ml IFN-γ or IFN-α, 100 ng/ml 
IL-6, IL-8, MCP-1, or TNF-α, or 300 ng/ml RANTES.  B) Infected cells were treated 
with the indicated concentrations of IFN-γ.  Mock, Mock-infected samples with no 
cytokine treatment; untreated, BKV-infected samples with no cytokine treatment; T = 0, 
samples harvested directly after one hour of adsorption with BKV. 
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BKV replication was not pursued at this time.  The dramatic inhibition of viral protein 
expression with IFN-γ treatment is the subject of further investigation in this study. 
 To determine whether IFN-γ exerts an inhibitory effect on BKV gene expression 
in a dose-dependent manner, RPTE cells were infected with BKV and treated with five-
fold dilutions of IFN-γ.  Total cell protein was harvested at four days post-infection and 
analyzed for TAg, VP1, and GAPDH expression by Western blotting (Figure 2.1B).  At 
the three higher doses (1250, 250, and 50 U/ml IFN-γ), levels of TAg were undetectable 
while at the three lower doses (10, 2, and 0.4 U/ml IFN-γ), TAg expression approached 
the level of the untreated sample.  At higher doses, VP1 expression was detectable but 
greatly reduced when compared to the untreated sample, and levels of VP1 increased as 
the dose of IFN-γ decreased.  Samples harvested directly after the initial infection (one 
hour incubation with viral lysates), denoted T = 0, were analyzed to determine the 
amount of detectable VP1 due to input virions, which was negligible (Figure 2.1B).  
Thus, levels of VP1 in all samples corresponded to de novo protein expression during 
infection.  Levels of GAPDH were similar for all samples, indicating equal protein 
loading and accounting for the general cellular effects of IFN-γ.  
IFN-γ does not affect the kinetics of BKV replication.  To determine whether IFN-γ-
mediated inhibition of viral gene expression was the result of a delay in the progression 
of infection or a reduction in the level of gene expression, we infected RPTE cells with 
BKV, treated with 50 or 250 U/ml IFN-γ, and harvested total cell protein at 12 hour 
intervals over four days (Figure 2.2A).  Samples were assayed for TAg, VP1, and 
GAPDH expression by Western blotting.  In both untreated samples and samples treated 
with 50 U/ml IFN-γ, TAg expression was first detected at 36 hours post-infection, while 
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VP1 expression was first detected at 48 hours post-infection, indicating that there was no 
delay in the initiation of viral gene expression.  Similar results were obtained from 
analysis of samples treated with 250 U/ml IFN-γ (data not shown).  An interesting pattern 
of viral gene expression was apparent in treated samples: the levels of TAg and VP1 
peaked at 72 and 84 hours post-infection, respectively, and then decreased at 96 hours 
post-infection (Figure 2.2A).  This level of inhibition of viral gene expression was 
maintained up to 13 days post-infection (data not shown).   
To examine the effect of IFN-γ on the timing and level of viral progeny produced, 
viral lysates were harvested at T = 0 and 1, 2, 3, 4, and 6 days post-infection from BKV-
infected RPTE cells either untreated or treated with 50 or 250 U/ml IFN-γ.  The titer of 
each lysate was determined by fluorescent focus assay, which detects the expression of 
TAg in newly infected cells (Figure 2.2B).  The increase in viral titer of untreated and 
IFN-γ-treated samples was similar during the first 48 hours of infection, after which the 
untreated samples abruptly increased in viral titer whereas the IFN-γ-treated samples 
maintained the slower rate of increase seen in the first 48 hours.  Interestingly, the viral 
titers of both untreated and IFN-γ-treated samples reached a plateau at four days post-
infection; however, the titers of the IFN-γ-treated samples were approximately 16- and 
20-fold lower (for 50 and 250 U/ml IFN-γ-treated samples, respectively) than the 
untreated samples at six days post-infection.  The timing of viral protein expression and 
progeny production were similar for untreated samples and samples treated with 50 or 
250 U/ml IFN-γ, and comparable results were obtained when cells were treated with 
IFN-γ prior to infection (data not shown).  These data suggest that IFN-γ inhibits the level 






Figure 2.2.  BKV replication kinetics in the presence of IFN-γ.  RPTE cells were 
infected with the TU strain of BKV at an MOI of 0.5, treated with 50 (Figure 2.2A, 2.2B) 
or 250 U/ml (Figure 2.2B) IFN-γ at three to six hours post-infection.  A) Total cell 
protein was harvested every 12 hours for four days.  Samples were analyzed by Western 
blot, probing for TAg, VP1, and GAPDH.  Untreated, BKV-infected samples with no 
IFN-γ treatment; M, mock-infected samples; hpi, hours post-infection; 0 hpi, samples 
harvested directly after one hour absorption with BKV (to detect protein from input 
virions).  B) Viral lysates were harvested at 0, 1, 2, 3, 4, and 6 days post-infection and 
progeny production was determined by the fluorescent focus assay. Data are represented 
as the log of the viral titer in infectious units per ml (IU/ml) and samples were assayed in 
triplicate.  Error bars are too small to be seen for some samples.  
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rules out a block at entry or trafficking to the nucleus as the mechanism of IFN-γ 
inhibition. 
Treatment with IFN-γ results in a reduction in the level of early region transcripts.  
The previous experiments demonstrated the inhibitory effect of IFN-γ on the level of viral 
protein expression and progeny production.  To determine whether IFN-γ-mediated 
inhibition occurs at the level of transcription or translation, we examined the effect of 
IFN-γ on viral transcript production.  Total cell RNA was harvested at 48 or 96 hours 
post-infection from RPTE cells infected with BKV and treated with 50 or 250 U/ml 
IFN-γ.  RNA samples were analyzed by real time reverse-transcription PCR (real time 
RT-PCR) to detect the levels of TAg transcripts.  By designing the TAg primers and 
probe set to amplify a 90-base pair amplicon across the splice site of the early region, 
amplification was limited to the amplicon produced from the TAg cDNA template, as 
opposed to that from the tAg or unspliced cDNA template.  Results were normalized to 
the levels of GAPDH transcripts to account for the non-specific cellular effects of IFN-γ, 
using the 2-ΔΔC(T) method and are presented as the fold change in TAg transcript levels, 
with the levels in samples treated with 250 U/ml IFN-γ arbitrarily set to one.  
 At 48 hours post-infection, there was a modest 1.6-fold decrease in TAg transcript 
levels with 50 and 250 U/ml IFN-γ treatment (Figure 2.3A).  These results were 
confirmed by Northern blot analysis, using a probe specific for the entire BKV early 
region to detect levels of all species of early region transcripts (data not shown).  A 
similar level of inhibition was observed at 48 hours post-infection at the level of protein 
expression (Figure 2.2A).  At 96 hours post-infection, there was a more dramatic and 





Figure 2.3.  Effect of IFN-γ on viral early region transcript levels.  RPTE cells were 
infected with the TU strain of BKV at an MOI of 0.5, treated with 50 or 250 U/ml IFN-γ 
at three to six hours post-infection, and total cell RNA was prepared at (A) 48 or (B) 96 
hours post-infection.  The level of TAg transcripts in each sample was determined using 
real time RT-PCR, normalizing to level of GAPDH transcripts; samples treated with 250 
U/ml IFN-γ were arbitrarily set to one.  Each bar represents the average of two (Figure 
2.3A) or three (Figure 2.3B) independent experiments analyzed in triplicate in the same 
assay.  Mock, mock-infected samples with no IFN-γ treatment; untreated, BKV-infected 
samples with no IFN-γ treatment.   
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250 U/ml IFN-γ resulted in 6.6-fold (P < 0.005) and 12.1-fold (P < 0.004) reductions in 
TAg transcript levels, respectively (Figure 2.3B).  These findings are consistent with our 
previous observations of the protein levels at 96 hours post-infection (Figure 2.2A).  The 
relative correlation of real time RT-PCR data (measuring the effect of IFN-γ on the 
steady-state level of TAg mRNA) and observations made from Western blot analysis 
(showing the effect of IFN-γ on the level of viral protein expression) suggest 
predominately IFN-γ-mediated effects on transcription.  However, IFN-γ may also 
mediate an inhibitory effect at the level of translation.  Future studies on the mechanism 
of inhibition will provide more insight on this subject.   
Effect of IFN-γ during infections with different MOIs.  To investigate whether the 
inhibitory effect of IFN-γ is dependent on levels of input virus, RPTE cells were infected 
with five-fold dilutions of BKV.  These infections of varying MOIs may represent 
different stages of BKV infection in the host.  For example, an infection at an MOI of 0.1 
might be similar to the subclinical state of persistence seen in immunocompetent hosts, 
while an infection at an MOI of 12.5 might be more similar to the reactivation and lytic 
infection of BKV preceding the development of PVN in immunosuppressed hosts.  
Infected cells were treated with 50 or 250 U/ml IFN-γ and total cell protein was harvested 
at two, three, and four days post-infection for analysis of viral protein expression by 
Western blotting (Figure 2.4A, 2.4B).  Regardless of the MOI used during the infection, 
TAg and VP1 expression were strongly inhibited with IFN-γ treatment and peak protein 
levels occurred at three days post-infection, similar to the pattern seen in previous 
experiments.  Not surprisingly, levels of TAg and VP1 expression were higher in samples 




Figure 2.4.  Effect of IFN-γ during infections with different MOIs.  RPTE cells were 
infected with the TU strain of BKV at MOIs of 12.5, 2.5, 0.5, or 0.1 and treated with 50 
U/ml (Figure 2.4A, 2.4B, 2.4C) or 250 U/ml (Figure 2.4C) IFN-γ at three to six hours 
post-infection.  A and B) Total cell protein was harvested at two, three, and four days 
post-infection and analyzed by Western blot, probing for TAg, VP1, and GAPDH.  The 
analysis of total cell protein harvested from infection at an MOI of 0.5 was repeated in 
Figure 2.4B for direct comparison to samples from infection at an MOI of 0.1.  M, mock-
infected samples with no IFN-γ treatment; dpi, days post-infection.  C) Viral lysates were 
harvested at T = 0 (after one hour absorption with BKV) and four days post-infection and 
viral progeny production was determined by the fluorescent focus assay.  Data are 
represented as the log of the viral titer in infectious units per ml (IU/ml) and samples 
were assayed in triplicate.  Untreated, BKV-infected samples with no IFN-γ treatment.  
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reduction in viral gene expression compared to untreated samples with the same infection 
conditions.  These data suggest that IFN-γ-mediated inhibition may be important for 
controlling BKV replication in both immunocompetent and immunosuppressed hosts.  
Viral lysates were harvested at four days post-infection from cells infected in 
these same conditions and analyzed for viral progeny production using the fluorescent 
focus assay.  While significant inhibitory effects mediated by IFN-γ were seen in all 
treated samples (for MOIs of 12.5, 2.5, 0.5, P < 0.05; for MOI of 0.1, P = 0.05), the effect 
was greater when less input virus was used during the infection (Figure 2.4C).  Cells 
treated with IFN-γ and infected at an MOI of 0.1 showed an almost 80-fold reduction in 
viral progeny production, while cells infected at an MOI of 12.5 (7-fold reduction), 2.5 
(13-fold reduction), and 0.5 (53-fold reduction) were affected less severely by IFN-γ 
treatment.  A comparison of viral titers of IFN-γ-treated samples with those of input virus 
(T = 0) showed that BKV progeny were produced in the presence of IFN-γ.  This 
suggests that, despite the inhibitory effects observed, IFN-γ is not driving BKV infection 
into a state of latency, in which the complete absence of late gene expression and progeny 
production would be expected.  
Response of various BKV strains to IFN-γ treatment.  To determine whether the 
inhibitory effect of IFN-γ on viral replication and gene expression is consistent for 
different strains of BKV, we infected RPTE cells with the TU strain, which was used 
throughout the above experiments, and two additional strains, Dunlop and Proto-2.  Cells 
were treated with 50 or 250 U/ml IFN-γ and total cell protein was harvested at two, three, 
and four days post-infection for analysis of viral protein expression by Western blotting 
(Figure 2.5A).  For each strain, TAg and VP1 expression were strongly inhibited by 
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treatment with 50 U/ml IFN-γ and as before, viral protein levels in treated samples 
peaked at three days post-infection (Figure 2.5A).  Results were similar for samples 
treated with 250 U/ml IFN-γ (data not shown).  These data suggest that all strains of BKV 
may respond similarly to IFN-γ-mediated inhibition of viral gene expression.  In addition, 
viral lysates were harvested at the initiation of infection (T = 0) and four days post-
infection from RPTE cells infected with the three BKV strains and treated with 50 or 250 
U/ml IFN-γ (Figure 2.5B).  IFN-γ treatment significantly inhibited progeny production 
for each of the strains (P < 0.05): viral titer was reduced in the presence of IFN-γ by as 
much as 456-fold for infection with the Dunlop strain, 114-fold for infection with the 






Figure 2.5.  Response of various BKV strains to IFN-γ treatment.  RPTE cells were 
infected with the TU, Dunlop, or Proto-2 strains of BKV at an MOI of 0.5 and treated 
with 50 U/ml (Figure 2.5A, 2.5B) or 250 U/ml (Figure 2.5B) IFN-γ at three to six hours 
post-infection.  A) Total cell protein was harvested at two, three, and four days post-
infection and analyzed by Western blot, probing for TAg, VP1, and GAPDH.  M, mock-
infected samples with no IFN-γ treatment; dpi, days post-infection.  B) Viral lysates were 
harvested at T = 0 (after one hour absorption with BKV) and four days post-infection and 
viral progeny production was determined by the fluorescent focus assay.  Data are 
represented as the log of the viral titer in infectious units per ml (IU/ml) and samples 
were assayed in triplicate.  Untreated, BKV-infected samples with no IFN-γ treatment. 
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Discussion 
 Polyomavirus nephropathy is a complication associated with kidney 
transplantation resulting from the reactivation of BKV.  Our knowledge about the 
immune response to BKV is limited, making the management of PVN difficult.  The 
experiments described in this paper begin to characterize the inhibitory effect of IFN-γ on 
the lytic infection of proximal tubule epithelial cells by BKV.  We have shown that IFN-γ 
specifically inhibits viral gene expression and progeny production in a dose-dependent 
manner.  In addition, infected cells exposed to IFN-γ have lower levels of TAg transcripts 
than untreated cells, suggesting that IFN-γ-mediated inhibition occurs at the level of 
transcription.  Cells infected with different MOIs of BKV responded similarly to 
treatment with IFN-γ; however the more virus present, the weaker the inhibitory effect.  
In addition, IFN-γ had a significant inhibitory effect on viral gene expression and 
progeny production during infections with three different strains of BKV.  These findings 
suggest that IFN-γ plays an important role in regulating BKV infection.     
It is important to note that samples treated with IFN-γ maintained detectable de 
novo viral gene expression and progeny production.  It is unclear whether this is a result 
of a low level of viral replication in all cells due to incomplete inhibition by IFN-γ, or a 
normal level of replication in a fraction of cells that were unresponsive to IFN-γ.  In the 
latter scenario, IFN-γ may force BKV into a state of latency in responsive cells.  
However, the finding that viral replication continued to some extent in the presence of 
IFN-γ correlates well with the observation that healthy immunocompetent individuals 
shed BKV in their urine periodically throughout their lives.  A reduction of IFN-γ 
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production by antigen-specific T lymphocytes in immunosuppressed patients may be, in 
part, responsible for reactivation and subsequent development of BKV-associated 
disease.  
An interesting pattern of viral gene expression was noted in samples exposed to 
IFN-γ: protein levels, though severely reduced when compared to untreated samples, 
peaked at three days post-infection and then declined until a steady, low level of 
expression was reached.  We hypothesize that treatment with IFN-γ may either shorten 
the duration of TAg expression or force the virus into a persistent or latent state.  Since 
we observed progeny production at times when TAg expression was either very low or 
undetectable by Western blot, a minimal threshold level of TAg seems to be sufficient to 
facilitate the progression of a productive BKV infection. 
Activation of the IFN-γ signaling cascade as a result of IFN-γ binding to the 
surface receptor has a multitude of effects on the cell (Schroder et al., 2004; Sen, 2001).  
IFN-γ has overall anti-proliferative and pro-apoptotic effects, mediated primarily by 
protein kinase R and IRF-1, respectively.  In our studies, we have accounted for these 
non-specific cellular effects by normalizing each sample to the levels of a housekeeping 
gene, GAPDH or to cell number.  IFN-γ signaling also plays a major role in activating 
and recruiting cells of the immune system, for example, by up-regulating the surface 
expression of MHC class I and II molecules and inducing expression of inflammatory 
cytokines.  However, the system we used to study the lytic infection of BKV does not 
incorporate cells of the immune system and thus eliminates immune activation from the 
potential mechanisms of IFN-γ-specific inhibition of BKV replication.  In addition, IFN-γ 
signaling activates the type I IFN cascade, which establishes a general antiviral 
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environment within the cell.  However, the direct treatment of infected cells with IFN-α 
has little effect on viral gene expression (Figure 2.1A).  The last major category of IFN-γ 
signaling effects involves the activation or repression of transcription factors that regulate 
the expression of genes.  We speculate that the mechanism by which IFN-γ inhibits BKV 
replication employs regulatory transcription factors that act on the early and late viral 
promoters.  However, regulation of the early promoter to inhibit TAg expression alone 
would be sufficient to explain a decrease in levels of TAg, VP1, and viral progeny 
production, since TAg is a key mediator of the progression of the BKV life cycle.  IFN-γ-
activated transcription factors include members of the STAT and IRF family, ISGF3, c-
Myc, and c-Jun, as well as other factors affected by downstream elements of the IFN-γ 
signaling cascade and subsequently regulated at a later time (de Veer et al., 2001; Der et 
al., 1998).  We are currently investigating candidate IFN-γ-regulated factors that may be 
responsible for the inhibitory effects on BKV.     
The non-coding control region (NCCR) is the region of greatest variability 
between different strains of BKV.  Rearrangements of the transcription factor binding 
blocks (designated O-P-Q-R-S in the archetypal BKV strain WW) occur frequently in 
tissue culture systems and seem to arise in individuals with high viral loads or 
reactivation.  We examined the responses of three different strains of BKV to IFN-γ 
treatment during lytic infection.  BKV TU (NCCR structure: O-P-Q-R1-12-P16-68-Q1-35-R52-
63-S) and BKV Dunlop (O-P-P1-7;26-68-P1-64-S) are strains commonly found in 
immunocompetent individuals, while BKV Proto-2 (O-P-P1-7;26-68-P-Q1-28-S7-63) was 
isolated from the urine of HIV-infected patients (Doerries et al., 1994; Moens and 
Rekvig, 2001; Sundsfjord et al., 1994; Sundsfjord et al., 1990).  The observation that 
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IFN-γ is able to inhibit viral gene expression and progeny production of three different 
strains of BKV with dissimilar NCCR structures suggests that our findings may be 
applicable to all strains of BKV.  Therefore, we speculate that transcription factor binding 
sites common to all three NCCRs (and potentially to most BKV strains) mediate the 
inhibitory effect of IFN-γ on the viral promoters.   
 It is still not understood what factors cause certain kidney transplant patients to 
undergo reactivation of BKV and develop PVN, while others on the same 
immunosuppressive regimen do not.  One possibility involves differences in host 
genetics.  For example, genetic polymorphisms of the IFNG gene may render some 
patients more susceptible to BKV reactivation than others.  Polymorphisms are frequent 
in the promoter region of the IFNG gene and affect the level of IFN-γ normally produced 
in the body (Pravica et al., 1999; Pravica et al., 2000).  Recent reports attempt to establish 
a correlation between certain IFNG polymorphisms and susceptibility to various diseases, 
including HPV-induced cervical cancer (Lai et al., 2005), tuberculosis (Lopez-Maderuelo 
et al., 2003), and parvovirus B19 infections (Kerr et al., 2003).  It is possible that kidney 
transplant patients with IFNG polymorphisms resulting in lower levels of IFN-γ 
production are naturally more susceptible to reactivation of BKV under 
immunosuppressive therapies.  Screening of patients for such polymorphisms may help to 
determine the appropriate level of immunosuppression required to prevent graft rejection 
but still maintain the ability of the immune system to repress BKV reactivation.  In 
addition, treatment with IFN-γ may prove beneficial as an alternative to reducing 
immunosuppressive therapies upon detection of active BKV replication.  There are 
precedents for successful interferon therapy: IFN-α has been used to treat a wide-range of 
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cancers, hepatitis B virus, and hepatitis C virus, while IFN-γ has proven effective against 
chronic granulomatous disease (Pestka et al., 2004).    
 In conclusion, IFN-γ has a potent inhibitory effect on BKV gene expression, both 
at the level of transcription and translation, and viral progeny production in proximal 
tubule cells.  This effect is similar for the three different strains of BKV examined and is 
more effective at inhibiting gene expression and progeny production in the presence of 
less virus.  The exact mechanism of IFN-γ-mediated inhibition is not yet known, but we 
speculate that the activity of the BKV promoters is regulated by IFN-γ responsive 
transcription factors.  These findings expand the characterization of the host immune 
response to BKV and may lead to new approaches for the prevention of BKV reactivation 
in kidney transplant recipients.   
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 BK virus (BKV) is a human polyomavirus that has a well-established role in 
complications following transplantation and immunosuppression (Comoli et al., 2006; 
Nickeleit and Mihatsch, 2006).  In particular, BKV is the causative agent of 
polyomavirus nephropathy (PVN) in up to 10% of kidney transplant recipients, resulting 
in loss of graft function in 10-80% of those affected (Hirsch et al., 2006).  BKV 
reactivation is also associated with hemorrhagic cystitis (HC) in bone marrow transplant 
recipients, with approximately 50% of patients with active BKV viruria progressing to 
HC (Bedi et al., 1995; Pavlakis et al., 2006).  Despite extensive investigation, there has 
been limited success in identifying antiviral treatments for BKV reactivation and lytic 
infection (Josephson et al., 2006; Trofe et al., 2006).  Typically, upon diagnosis of BKV 
reactivation and PVN, the immunosuppressive regimen of the patient is reduced to allow 
the immune system to fight the viral infection.  This approach, however, increases the 
risk of graft rejection.  Thus it is important to investigate the immune response to BKV to 
identify immune components that control viral replication.
CHAPTER III  
TRANSFORMING GROWTH FACTOR-BETA-MEDIATED REGULATION OF 
BK VIRUS GENE EXPRESSION 
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BKV was first isolated from the urine of a kidney transplant patient with ureteral 
stenosis in 1971 (Gardner et al., 1971).  Primary infection with BKV occurs early in 
childhood, with seroconversion occurring by the age of 10 in up to 80% of the human 
population (Knowles, 2006).  Following the primary infection, BKV undergoes viremic 
dissemination and establishes a lifelong persistent infection primarily in the cells of the 
kidney and urinary tract (Chesters et al., 1983; Heritage et al., 1981).  More specifically, 
tubular epithelial cells of the kidney and epithelial cells of the urinary tract are major sites 
of BKV persistence and reactivation (Doerries, 2006; Nickeleit and Mihatsch, 2006).  
BKV has a non-enveloped, icosahedral virion composed of three proteins, VP1, 
VP2, and VP3, which encapsidate a circular double-stranded DNA genome of 
approximately 5.2 kb.  The genome can be divided into three distinct regions: the early 
region, which contains the coding sequences for large tumor antigen (TAg) and small 
tumor antigen (tAg); the late region, which contains the coding sequences for VP1, VP2, 
VP3, and agnoprotein; and the non-coding control region (NCCR), which contains the 
origin of replication and the viral early and late promoters.  The NCCR is used to 
distinguish one strain of BKV from another because of the propensity of this region to 
acquire point mutations and structural rearrangements (Moens and Van Ghelue, 2005).  
BKV strains can be divided into two classes: archetypal (pre-rearranged) strains, 
presumed to be the infectious and transmissible virus, and rearranged strains, which are 
predominately isolated from tissue biopsy samples (Cubitt, 2006).  The NCCRs of 
archetypal strains are structurally divided into blocks of transcription factor binding sites, 
arbitrarily designated O (142 bp, containing the origin of replication, TATA box, and 
TAg binding sites), P (68 bp), Q (39 bp), R (63 bp), and S (63 bp) (Markowitz and 
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Dynan, 1988; Moens et al., 1995).  Rearranged BKV strains result from the restructuring 
of the archetypal NCCR, such that certain blocks (primarily P, Q, and R) are, in whole or 
in part, duplicated or deleted (Moens and Van Ghelue, 2005).   
It is commonly reported that the predominant NCCR configuration actively shed 
in urine is archetypal (Markowitz et al., 1991; Negrini et al., 1991; Sharma et al., 2007; 
Sundsfjord et al., 1999; Takasaka et al., 2004), and that NCCR rearrangements seem to 
be isolated more frequently from the tissues and sera of patients with high viral loads 
(Boldorini et al., 2001; Gosert et al., 2008; Stoner et al., 2002).  In addition, changes in 
the NCCR structure arise spontaneously in tissue culture and these rearrangements 
enhance the ability of the virus to replicate and transform cells (Rubinstein et al., 1991; 
Watanabe and Yoshiike, 1985; Watanabe and Yoshiike, 1986).  It is possible that changes 
in the viral promoter region can also result in altered pathogenesis, such as a heightened 
ability to reactivate or disseminate.  Furthermore, rearrangements may affect the cell 
tropism of BKV, allowing infection of other cell types in addition to kidney and urinary 
epithelial cells.  The confounding observation, however, is that as of yet there is no 
apparent correlation between BKV NCCR structure and clinical outcome (Sharma et al., 
2007). 
TGF-β is a secreted cytokine having three isoforms in mammals (TGF-β1, TGF-
β2, TGF-β3), all with similar functions involved in the regulation of cell proliferation, 
differentiation, and immune suppression (Feng and Derynck, 2005; Li et al., 2006).  
TGF-β is produced by many different cell types, including renal epithelial cells, a major 
site of BKV reactivation.  Interestingly, the expression of TGF-β is enhanced in the 
presence of immunosuppressive therapies commonly administered to renal transplant 
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patients (Khanna et al., 1999a; Khanna et al., 1999b; McMorrow et al., 2005; Shihab et 
al., 1996).  We hypothesized that TGF-β would have an upregulatory effect on BKV gene 
expression and replication, correlating with the evident reactivation of BKV in kidney 
transplant recipients.   
TGF-β is initially expressed as an inactive complex of precursor polypeptides that 
undergoes activation by proteolytic cleavage.  Upon maturation, TGF-β can bind to TGF-
β receptor II dimers, resulting in the recruitment and phosphorylation of TGF-β receptor I 
dimers (Shi and Massague, 2003).  Once activated, TGF-β receptor I recruits and 
phosphorylates Smad2 and Smad3 proteins, the primary components of the TGF-β 
signaling cascade (Massague et al., 2005).  Phosphorylated Smad2 and Smad3 proteins 
can then form a complex with Smad4, resulting in the nuclear translocation of these 
proteins.  This complex has some weak intrinsic DNA binding activity of its own, but is 
more effective in regulating TGF-β-dependent gene expression in conjunction with 
cellular transcriptional co-activators that have high DNA binding activity and specificity 
(Brown et al., 2007; Massague and Wotton, 2000; Shi et al., 1998).     
In this report, we characterize the effect of TGF-β on the lytic infection of BKV 
in renal proximal tubule epithelial (RPTE) cells and on the activity of the viral early 
region promoter.  We demonstrate that the response to TGF-β-mediated regulation is 
dependent on the strain of BKV and thus the NCCR structure.  We show that 
upregulation by TGF-β maps to a short region of the promoter that most likely contains 
two distinct transcription factor binding sites.  These findings demonstrate transcriptional 
regulation of BKV by a cytokine that is found at elevated levels in transplant patients. 
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Materials and Methods 
Cell culture and reagents.  Primary human renal proximal tubule epithelial cells (RPTE 
cells, Cambrex) were maintained in renal epithelial cell basal medium (REBM, Cambrex) 
supplemented with human epidermal growth factor, fetal bovine serum (FBS), 
hydrocortisone, epinephrine, insulin, triiodothyronine, transferrin, and GA-1000 as 
indicated for renal epithelial cell growth medium (REGM, supplements obtained as 
REGM SingleQuots, Cambrex).  HT-1080 cells (ATCC CCL-121) were maintained in 
Dulbecco’s Modified Eagle Medium (Gibco) containing 10% FBS (Cambrex), 100 
units/ml penicillin, and 100 µg/ml streptomycin (Cambrex).  Both RPTE and HT-1080 
cells were grown at 37°C with 5% CO2 in a humidified incubator.  Recombinant human 
TGF-β1, produced in A293 cells (Peprotech, Inc.), was reconstituted according to 
manufacturer’s recommendations and used at a concentration of 10 ng/ml.   
Viruses.  BKV stocks were prepared from genomic clones of TU (cloned into the EcoRI 
site of pGEM-7Zf(-)), and Dunlop and Proto-2 (cloned into the BamHI site of pBR322, 
gift of Peter Howley), as previously described (Abend et al., 2007).  The resulting crude 
viral stocks were titrated by fluorescent focus assay as previously described (Abend et al., 
2007) and the integrity of the NCCR was confirmed by sequencing of PCR products.    
Infections.  RPTE cells at 70% confluence were infected with the TU, Dunlop, or Proto-
2 strains of BKV in REGM at an MOI of 0.5 IU/cell (infectious units per cell), incubating 
for one hour at 37°C.  Viral lysates used for the infection were replaced with fresh 
REGM.  TGF-β was added at three to four hours post-infection (hpi).   
Western blotting.  Total cell protein was harvested at three days post-infection (dpi) 
using E1A lysis buffer (Harlow et al., 1986) supplemented with 5 μg/ml PMSF, 5 μg/ml 
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aprotinin, 5 μg/ml leupeptin, 0.05 M sodium fluoride, and 0.2 mM sodium orthovanadate.  
The Bio-Rad protein assay was used to determine the protein concentration of each lysate 
and 10 μg of protein were electrophoresed on an 4-20% Tris-glycine polyacrylamide gel 
(Lonza) and analyzed by Western blotting for the expression of viral early protein TAg 
and GAPDH as previously described (Abend et al., 2007). 
RNA extraction and cDNA synthesis.  Total cell RNA was harvested at 24, 36, 48, 72, 
and 96 hpi using TRIzol reagent (Invitrogen) according to manufacturer’s instructions.  
Samples were treated with DNase I (Promega) to reduce contaminating DNA, and RNA 
integrity was confirmed by electrophoresis on an agarose gel.  To generate cDNA, 
reverse transcription reactions were performed on 1 μg of input RNA using the iScript 
cDNA Synthesis Kit (Bio-Rad), according to manufacturer’s instructions.    
Real-Time PCR: TaqMan Assay.  Primers and probes used to assay TAg and GAPDH 
transcript levels are reported previously (Abend et al., 2007).  PCR reactions were 
performed in a total volume of 25 μl using TaqMan Universal PCR 2x master mix 
(Applied Biosystems), 2.5 μl cDNA template, 500 nM of each primer, and 200 nM probe.  
The iCycler iQ5 Real-Time Detection System (Bio-Rad) was used for amplification with 
the following PCR program: 2 min at 50°C; 10 min at 95°C; 40 cycles of denaturation at 
95°C for 15 sec and annealing and extension at 56°C for 1 min.  Results are presented as 
the fold change in TAg transcript levels, with the relative level observed at 24 hpi, 
untreated, arbitrarily set to one.  Results are normalized to the levels of GAPDH 
transcripts present using the 2-ΔΔC(T) (Livak) method (Livak and Schmittgen, 2001).   
Generation of luciferase constructs.  The NCCRs of four strains of BKV were 
amplified from their genomic clones using the primers  
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Agno1 (5’  AGTGCTAGCGCCTTTGTCCAGTTTAACT  3’) and  
LTAg2 (5’  AGTCTCGAGAAATAGTTTTGCTAGGCCTCA  3’), which contain the 
restriction endonuclease sites for NheI and XhoI, respectively (underlined).  Polymerase 
chain reactions utilizing these primers produced 350-400 bp fragments spanning the 
NCCR from the start codon of agnoprotein to 35 bp before the TAg start codon.  These 
fragments were first cloned into the pGEM-T Easy vector (Promega) and then subcloned 
into the luciferase vector pGL2-basic (Promega) by means of the NheI and XhoI sites.  In 
these resulting luciferase constructs (pGL2-TU, pGL2-Dik, pGL2-Dunlop, pGL2-Proto-
2), the BKV early promoter drives the expression of the firefly luciferase gene.     
Site-directed mutagenesis.  The following primers were synthesized and HPLC purified 
to introduce a point mutation (underlined) at nucleotide 362 (GenBank accession no. 
DQ305492) in the BKV TU NCCR: TU-SmtFOR (5’  TCGCAAAACATGT 
CTGTGTGGCTGCTTTCCGG  3’), TU-SmtREV (5’  CCGGAAAGCA 
GCCACACAGACATGTTTTGCGA  3’).  The following primers were synthesized and 
HPLC purified to insert 6 bp normally present only in the TU NCCR into the BKV Dik 
NCCR (underlined): Dik+6TUFOR (5’  AAACATGTCTGTCTGGCTGC 
TTTCCGGTTTCACTCCTTTGG 3’), Dik+6TUREV (5’  CCAAAGGAGTGAAACCG 
GAAAGCAGCCAGACAGACATGTTT  3’).  Mutagenesis was performed following the 
protocol for the QuikChange II Site-Directed Mutagenesis Kit (Stratagene) using the 
primer pairs at 1.25 nM each, 100 ng of pGL2-TU or pGL2-Dik as template, 1 mM 
dNTPs, and 1.25 U Native Pfu DNA Polymerase (Stratagene) in 25 μl total reaction 
volume.  The following two-step PCR program was used: 3 min at 95°C; 18 cycles of 
denaturation at 95°C for 15 sec and annealing and extension at 68°C for 12 min. 
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Luciferase assays.  RPTE or HT-1080 cells were grown in 12-well tissue culture-treated 
plates to 60% confluence.  Firefly luciferase constructs (pGL2-BKV strain) and a 
promoterless control Renilla luciferase plasmid (pRL-Null, Promega) were cotransfected 
into RPTE cells at a ratio of 9:1, with a total of 0.6 µg of DNA per well, using the 
Effectene Transfection reagent (Qiagen) according to manufacturer’s recommendations.  
TGF-β was added at three to four hours post-transfection (hpt) and total cell lysates were 
harvested at 48 hpt in 1x Passive Lysis Buffer (Promega).  Luciferase assays were 
performed on triplicate samples using the Dual-Luciferase Reporter Assay (Promega), 
according to manufacturer’s recommendations.  Results are expressed as relative light 
units (RLU) of firefly luciferase activity normalized to RLU of Renilla luciferase activity.  
TGF-β did not significantly affect the levels of Renilla luciferase activity (data not 
shown).  Statistical significance was determined using a two-tailed Student’s t test 
assuming unequal variance, and P values < 0.01 were considered significant.      
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Results and Discussion 
TGF-β-mediated regulation of BKV gene expression during infection.  We first 
investigated the regulatory potential of TGF-β on BKV gene expression during lytic 
infection of RPTE cells.  We examined the levels of TAg at three dpi in cells infected 
with three strains of BKV that differ significantly in their NCCR structures:  TU (O-P-Q-
R1-12-P16-68-Q1-35-R52-63-S), Dunlop (O-P-P1-7;26-68-P1-64-S), and Proto-2 (O-P-P1-7;26-68-P-
Q1-28-S7-63).  TGF-β only significantly affected the expression of viral proteins in cells 
infected with the TU strain of BKV, as shown by the upregulation of TAg levels (Figure 
3.1A).  TAg expression remained relatively unchanged in cells infected with the Dunlop 
and Proto-2 strains.  To demonstrate that the effect was specific to viral gene expression 
and not a result of TGF-β-mediated inhibition of epithelial cell proliferation, samples 
were also analyzed for levels of GAPDH, a cellular housekeeping gene.  These results 
indicate that the presence of TGF-β affects BKV gene expression in a strain-specific 
manner.   
To determine whether TGF-β-mediated regulation occurs during transcription or 
translation, we examined the levels of early gene transcripts during the course of BKV 
TU infection.  Total cell RNA was harvested at 24, 36, 48, 72, and 96 hpi and analyzed 
by a real-time RT-PCR assay to detect TAg transcripts in the absence or presence of 
TGF-β (Figure 3.1B).  Results were normalized to the levels of GAPDH mRNA present 
in the samples.  TGF-β had a prominent effect on TAg transcription at early time points, 
with 2.5-fold upregulation in transcript levels at 24 and 36 hpi, and 3.3-fold upregulation 
over untreated cells at 48 hpi.  At the later stages of infection the effect of TGF-β was 






Figure 3.1.  TGF-β upregulates BKV TU gene expression during infection.  A) RPTE 
cells were infected with the indicated strains of BKV at an MOI of 0.5 IU/cell and treated 
with 10 ng/ml TGF-β at three to four hpi.  Total cell protein was harvested at three dpi 
and analyzed by Western blot, probing for TAg and GAPDH.  Mock, mock-infected 
samples with no TGF-β treatment.  B) RPTE cells were infected with the TU strain of 
BKV at an MOI of 0.5 IU/cell in the presence or absence of 10 ng/ml TGF-β, and total 
cell RNA was prepared at 24, 36, 48, 72, and 96 hpi.  Relative TAg transcript levels were 
determined using real time RT-PCR, normalizing to levels of GAPDH transcripts in each 
sample.  One representative experiment is shown; triplicate samples were analyzed in the 
same assay.  Fold expression of TAg at 24 hpi, untreated was arbitrarily set to one.  
Mock, mock-infected samples with no TGF-β treatment.   
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hpi.  These results suggest that TGF-β-mediated regulation occurs at the level of 
transcription.  Furthermore, the timing and limited duration of the upregulation suggest 
that transcription factors involved in the TGF-β signaling cascade are responsible for the 
effect.      
BKV early promoter activity in the presence of TGF-β.  We next set out to examine 
the effect of TGF-β on the viral early promoter.  We cloned the NCCRs of four BKV 
strains [TU, Dunlop, Proto-2, Dik (archetypal)] into a luciferase reporter plasmid, such 
that the viral early promoter drives the expression of the firefly luciferase gene.  This 
assay permitted us to examine the effect of TGF-β on promoter activity in the absence of 
viral gene expression and other BKV genomic sequences.  RPTE cells were cotransfected 
with the BKV promoter-driven luciferase plasmids and a promoterless control Renilla 
luciferase plasmid in the absence or presence of TGF-β, and lysates were assayed for 
luciferase activity at 48 hpt (Figure 3.2A).  The results confirmed that only the TU early 
promoter was affected by TGF-β treatment, while the other three viral promoters showed 
no significant change in activity in the presence of TGF-β (1.4-, 1.1-, and 1.1-fold change 
for Dik, Dunlop, and Proto-2 promoters, respectively).  The 2.5-fold upregulation (P = 
0.009) in TU promoter activity was similar to that seen during BKV infection of RPTE 
cells (Figure 3.1).  The results of this assay suggest that the effect of TGF-β is mediated 
solely at the promoter and is therefore driven by specific transcription factors.  
The regulation of BKV early promoter activity by TGF-β signaling may also 
depend on the cell type examined.  The luciferase assay described above was also 
performed in HT-1080 cells, a human fibrosarcoma cell line (Figure 3.2B).  The TU and 






Figure 3.2.  BKV early promoter activity in the presence of TGF-β.  A) RPTE cells 
were cotransfected with BKV early promoter-firefly luciferase constructs and a 
promoterless control Renilla luciferase plasmid.  TGF-β was added at three to four hpt 
and total cell lysates were harvested at 48 hpt.  Luciferase assays were performed on 
triplicate samples and data are represented as relative light units (RLU) of firefly 
luciferase activity, normalized to RLU of Renilla luciferase activity.  Data shown 
represent results obtained from three independent experiments.  B) HT-1080 cells were 
cotransfected with BKV early promoter-firefly luciferase constructs and a promoterless 
control Renilla luciferase plasmid and assayed as described in (A).  Data shown represent 
results obtained from three independent experiments. 
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activity was upregulated by 3.1-fold (P < 0.001) and Dik activity remained relatively 
unchanged (1.6-fold decrease, P < 0.001) in the HT-1080 cells.  However, the Dunlop 
and Proto-2 promoters were repressed in the presence of TGF-β in HT-1080 cells by 2.6- 
and 3.1-fold respectively (P < 0.001 and P = 0.002, respectively).  In addition to cells of 
the kidney and urinary tract, BKV sequences have been isolated from peripheral blood 
mononuclear cells (Chatterjee et al., 2000; Doerries et al., 1994), tonsils (Goudsmit et al., 
1982), and brain (De Mattei et al., 1995; Elsner and Doerries, 1992).  Thus, TGF-β-
mediated signaling may differentially regulate BKV during infections of other cell types. 
Having mapped the effect of TGF-β to the BKV promoter, we wanted to examine 
the differences between the TU NCCR and the other three NCCRs used in our studies.  
We performed an alignment of the four BKV NCCRs and observed that there was one 
region (7 bp, starred nucleotides) of the TU NCCR that did not align to any region of the 
Dik, Dunlop, or Proto-2 NCCRs (Figure 3.3).  We used the MatInspector transcription 
factor binding site prediction program (Cartharius et al., 2005) to analyze the potential 
binding sites in the viral promoters.  Within this unique sequence in the TU NCCR, the 
program predicted a binding site for the transcription factor ZEB-1/AREB6 with a high 
probability.  There were no predicted ZEB-1 binding sites in the other three NCCRs.  
ZEB-1 has been reported to interact with Smad3 and mediate TGF-β-dependent gene 
regulation (Postigo, 2003; Postigo et al., 2003).  Interestingly, in both the TU and Dik 
NCCRs the MatInspector program also predicted an adjacent binding site for the 










Figure 3.3.  Alignment of BKV NCCRs.  The segments of the NCCRs (TU, Dik, 
Dunlop, Proto-2) from the nucleotide before the start codon of agnoprotein through the P 
block directly adjacent to the O block are shown.  The O block is not shown because it is 
highly homologous between strains.  Bold type indicates nucleotides that are identical in 
at least three of the strains.  Underlined regions indicate the predicted Smad3 and ZEB-1 
binding sites.  Dots indicate nucleotides not found within a sequence.  The starred 
nucleotides indicate the region of the TU NCCR that does not align anywhere in the Dik, 
Dunlop, or Proto-2 NCCRs.  The early promoter is read from left to right (top to bottom), 
in the direction of the early coding region.  The late promoter is read from right to left 
(bottom to top), in the direction of the late coding region. 
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ZEB-1 site to the predicted Smad3 site in the TU NCCR suggests that a Smad3-ZEB-1 
complex could actively bind to the promoter and regulate early gene transcription.              
TU promoter sequences required for TGF-β-mediated regulation.  We used site-
directed mutagenesis to modify the luciferase plasmids to define the exact sequences 
required for TGF-β-dependent activation of the early promoter (Figure 3.4A).  Starting 
with the pGL2-TU plasmid as a template, we introduced a single base change (C to G) in 
the core of the predicted Smad3 binding site, resulting in the pGL2-TU-Smt plasmid.  
This mutation has previously been shown to effectively disrupt the ability of Smad 
proteins to bind to the DNA (Jonk et al., 1998).  In a similar manner, we modified the 
pGL2-Dik plasmid, which contains a predicted Smad3 binding site identical to that found 
in the TU NCCR, lacks a predicted ZEB-1 binding site, and is not affected by TGF-β.  
Using site-directed mutagenesis, we introduced six nucleotides (GGTTTC) to place a 
predicted ZEB-1 binding site in the same relative position and orientation as in the TU 
NCCR (pGL2-Dik+6TU). 
The wildtype and mutated luciferase reporter plasmids were transfected into 
RPTE cells in the absence or presence of TGF-β, and lysates were assayed for luciferase 
activity at 48 hpt (Figure 3.4B).  Similar to previous results, the TU early promoter was 
upregulated by 2.2-fold (P = 0.009) in the presence of TGF-β, while the Dik promoter 
showed little change in activity (1.2-fold increase).  The mutant TU promoter was also 
unresponsive to TGF-β treatment (1.2-fold decrease), suggesting that the putative Smad3 
site is required for TGF-β-dependent promoter activation and that the putative ZEB-1 site 
alone is not sufficient.  In addition, the mutant Dik promoter was upregulated by 2.7-fold 






Figure 3.4.  Regions of the TU promoter required for TGF-β-mediated regulation of 
BKV.  A) Schematic representation of promoter constructs.  TU-Smt has a single base 
change in the core of the predicted Smad3 binding site (hatched).  Dik+6TU has a 6 bp 
insertion that creates the predicted ZEB-1 binding site.  The early promoter is read from 
left to right, with the start codon for the firefly luciferase gene following the right end of 
the promoter.  B) RPTE cells were cotransfected with wildtype or mutant BKV early 
promoter-firefly luciferase constructs and a promoterless control Renilla luciferase 
plasmid.  TGF-β was added at three to four hpt and total cell lysates were harvested at 48 
hpt.  Luciferase assays were performed on triplicate samples and data are represented as 
relative light units (RLU) of firefly luciferase activity, normalized to RLU of Renilla 
luciferase activity.  Data shown represent results obtained from three independent 
experiments. 
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ZEB-1 sites are necessary for upregulation.  It is important to note that the mutations did 
not significantly change the basal activities of the promoters (Figure 3.4B: compare 
untreated, TU to TU-Smt; untreated, Dik to Dik+6TU).  These results suggest that 
regulation depends directly on the presence of binding sites for transcription factors 
involved in TGF-β signaling in the viral early promoter, and that the absence of such sites 
results in unresponsiveness to TGF-β.  
The MatInspector binding site predictions and the results of the luciferase assays 
strongly suggested that Smad3 and ZEB-1 regulate the TU promoter.  However, our 
attempts to show Smad3 and ZEB-1 binding to the viral promoter using three different 
assays, electrophoretic mobility shift assay (EMSA), anchored transcriptional promoter 
assay (Ravichandran and Major, 2006), and siRNA-mediated knockdown of Smad3 and 
ZEB-1, failed to demonstrate conclusively Smad3 and ZEB-1 binding to, or activation of, 
the TU promoter in the presence of TGF-β (data not shown).  It remains possible that 
Smad3 is acting with another transcription factor, or that the assays simply were not well 
suited for demonstration of binding of these particular factors in our system.  It will be of 
interest to define the nature of the factors mediating the TGF-β response in the future. 
Previous studies have shown the relevance of Smad-dependent TGF-β signaling 
during viral infections.  For example, JC virus (JCV)-infected oligodendrocytes have 
elevated levels of TGF-β, Smad3, and Smad4, and chloramphenicol acetyl transferase 
assays demonstrate the activating effect of Smad protein overexpression on the early and 
late viral promoters (Enam et al., 2004).  Recently, it was shown that TGF-β stimulates 
JCV replication and that MAPK kinase (MEK) inhibitors can block this effect, indicating 
a role for activated downstream transcription factors in TGF-β-mediated upregulation 
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(Ravichandran et al., 2007).  Epstein-Barr virus (EBV), a ubiquitous human 
gammaherpesvirus that, like BKV, has both latent and lytic stages of infection, is also 
regulated by TGF-β-mediated signaling.  Studies have shown that TGF-β treatment 
drives the reactivation of EBV lytic infection from latently-infected B cells (di Renzo et 
al., 1994) and epithelial cells (Fukuda et al., 2001).  These and other reports have 
established the relevance of TGF-β and Smad3 in viral regulation (Li et al., 2006; Reed, 
1999).   
Our studies of cytokine-mediated regulation of BKV gene expression and 
replication are targeted at understanding the process of viral reactivation in 
immunosuppressed transplant patients.  Previously, it has been shown that common 
immunosuppressive therapies used in renal transplantation patients, such as cyclosporine 
and tacrolimus, result in upregulation of TGF-β expression in various cell types, 
including kidney epithelial cells (Khanna et al., 1999a; Khanna et al., 1999b; McMorrow 
et al., 2005; Shihab et al., 1996).  Therefore, we hypothesized that TGF-β-mediated 
upregulation of the TU strain of BKV would result in an enhanced ability to reactivate in 
renal transplant recipients and, consequently, an increase in virulence of this particular 
strain.  However, there are few reports of the TU strain in clinical isolates (Sundsfjord et 
al., 1994; Sundsfjord et al., 1990), and we have been unable to identify other naturally 
occurring strains of BKV that contain both the sequences in the TU promoter that are 
required for TGF-β-mediated activation.  Nevertheless, the predicted Smad3 site occurs 
in a number of other strains [MAN10B (GenBank accession no. DQ176633), WWT 
(M34048), URO1 (U33549), TC-3 (AF164514), AS (M23122), TW-2 (AB213487), 
SJH85B (DQ176634), T2R.1BKreg-3-4 (AF442893), SA090600 (AF356532)], and 
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Smad3 is known to have many different functional binding partners, including AP-1, c-
MYC, NF-κB, and Sp1 (Brown et al., 2007), all of which also have binding sites in the 
NCCR.  The results of the luciferase assays using mutated promoters (Figure 3.4) support 
the likelihood that there are two transcription factors involved in regulating the response 
to TGF-β.  Thus, there is potential for TGF-β-mediated activation or repression of other 
BKV strains. 
Our studies provide evidence for the transcriptional regulation of BKV early gene 
expression by as yet unidentified components of the TGF-β signaling cascade.  However, 
the postulated contribution of TGF-β to BKV reactivation in transplant patients must be 
considered in the context of the overall immune status of those individuals.  Previously, 
we also described the inhibition of BKV replication by IFN-γ, in a strain-independent 
manner (Abend et al., 2007).  It is therefore reasonable to posit that reactivation of BKV 
in immunocompromised patients may require multiple signals, such as the enhancement 
of viral gene expression by TGF-β and the absence of IFN-γ-mediated inhibition of 
replication, as well as others.  Understanding the contributions of each signal to the 
outcome of the infection will be critical for building a complete picture of the interaction 
between BKV and the host immune system.  
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BK virus (BKV) is a ubiquitous pathogen that infects nearly the entire population 
by the age of 10 (Knowles, 2001; Knowles et al., 2003).  The transmission of BKV is not 
yet characterized but is thought to occur by either the respiratory or urino-oral route.  
Following a typically subclinical primary infection, BKV is able to disseminate and 
establish an infection of kidney epithelial cells, particularly proximal tubule epithelial 
cells, and the urothelium (Chesters et al., 1983; Heritage et al., 1981).  It is within these 
cells that the virus persists throughout the life of the host.  Although BKV does not 
typically cause disease in healthy individuals, the virus is periodically shed in the urine 
(Knowles, 2001; Zhong et al., 2007).  In immunosuppressed patients, BKV can cause 
severe disease by reactivating to a robust lytic infection.  Approximately 10% of renal 
transplant recipients undergo BKV reactivation that develops into polyomavirus 
nephropathy (PVN), a lytic infection of kidney epithelial cells that can result in loss of 
function or destruction of the graft.  In addition, approximately 10% of bone marrow 
transplant recipients suffer from BKV reactivation, resulting in hemorrhagic cystitis 
(HC), a painful infection of bladder epithelial cells characterized by hematuria.   
CHAPTER IV 
PRELIMINARY RESULTS ON THE CHARACTERIZATION OF 
INTERFERON-GAMMA-MEDIATED REGULATION AND ARCHETYPE      
BK VIRUS REPLICATION IN A TISSUE CULTURE SYSTEM  
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BKV is a member of the polyomavirus family and is highly homologous to JC 
virus (JCV), the other human polyomavirus, and SV40, the well-studied simian virus 
(Cubitt, 2006; Imperiale, 2001).  BKV has a small (40-45 nm), nonenveloped icosahedral 
virion and a circular, double-stranded DNA genome of approximately 5.2 kb.  The 
genome can be divided into three major regions: the early coding region, which contains 
the genes for large tumor antigen (TAg), small tumor antigen (tAg), and truncated tumor 
antigen (truncTAg; D. Das, A. Joseph, J. Abend, D. Campbell-Cecen, and M. Imperiale, 
in preparation); the late coding region, which contains the genes for capsid proteins VP1, 
VP2, and VP3, and agnoprotein, which does not yet have a defined function; and the non-
coding control region (NCCR), which contains the origin of replication and the early and 
late promoters, which function in a bidirectional manner.  In the nucleus of the infected 
cell, BKV genomic DNA becomes associated with the cellular histones H2A, H2B, H3 
and H4 to form a viral minichromosome that is then packaged into virions (Meneguzzi et 
al., 1978).   
This chapter will describe preliminary results from two areas of research that 
follow from the work presented in Chapters II and III.  The first area of research is a 
continuation of the study of interferon-gamma (IFN-γ) mediated inhibition of BKV 
replication, with a focus on the characterization of chromatin remodeling events.  The 
second area of research is aimed at identifying factors that are required for archetype 
BKV strains to replicate in a tissue culture system.  It is possible that our findings in this 
area will also be linked to chromatin remodeling events, implicating chromatin structure 
as an important mechanism for regulating BKV replication.  
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Materials and Methods 
Cell culture and reagents.  Primary human renal proximal tubule epithelial cells (RPTE 
cells, Cambrex) were maintained for up to six passages in renal epithelial cell basal 
medium (REBM, Cambrex) supplemented with human epidermal growth factor, fetal 
bovine serum (FBS), hydrocortisone, epinephrine, insulin, triiodothyronine, transferrin, 
and GA-1000 as indicated for renal epithelial cell growth medium (REGM, supplements 
obtained as REGM SingleQuots, Cambrex).  RPTE cells were grown at 37°C with 5% 
CO2 in a humidified incubator.  Recombinant human IFN-γ (Peprotech, Inc) was 
reconstituted according to manufacturer’s recommendations and used at 50 U/ml or 250 
U/ml.  Trichostatin A (TSA, Sigma) and sodium butyrate (NaB, Sigma) were 
reconstituted according to manufacturer’s instructions and used at 1.32 μM and 5 mM, 
respectively.  
Viruses and infections.  The genome of BKV strain TU was cloned into pGEM-7zf(-) at 
the EcoRI site.  The genome of BKV strain Dik (archetype) was cloned into pBR322 at 
the BamHI site (gift of J. Lednicky).  BKV TU viral stocks were prepared and titrated as 
previously described (Abend et al., 2007).  RPTE cells were infected at 70% confluence 
with BKV TU at an MOI of 0.5 IU/cell (infectious units per cell) and incubated at 37°C 
for one hour.  The viral lysate used for infection was then replaced with fresh REGM.  
The dose and time of treatment with IFN-γ, TSA, or NaB is described in the figure 
legends. 
Transfections.  BKV genomic clones were prepared for transfection as follows: pGEM-
7-TU and pBR322-Dik were digested with EcoRI or BamHI, respectively, recircularized 
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with T4 DNA ligase, and phenol-chloroform extracted.  RPTE cells were transfected at 
50% confluence using Effectene (Qiagen) and the following conditions: 0.6 μg DNA per 
well of a 12-well plate with a DNA to Effectene ratio of 1:20.  In the cotransfection 
experiment (Figure 4.7), cells were transfected with 0.5 μg of BKV genomic DNA and 
0.1 μg of the TAg expression plasmid (pcDNA3.1 with TAg cDNA cloned into the 
BamHI and EcoRV sites).   
Low molecular weight DNA preparations.  Low molecular weight DNA was isolated 
from cells using a modified Hirt protocol (Hirt, 1967).  Cells were collected and pelleted 
at 300 x g for 5 min at 4°C.  Cell pellets were resuspended in Lysis buffer (0.6% SDS, 10 
mM EDTA) and incubated at room temperature (RT) for 20 min.  Sodium chloride 
(NaCl) was added to a final concentration of 1.4 M and the samples were incubated 
overnight at 4°C to precipitate the cellular genomic DNA, which was then pelleted at 
20,000 x g for 20 min at 4°C.  The supernatants were incubated with 1.5 μg/μl Pronase E 
and 150 ng/μl RNAse A for one hour at 37°C.  Samples were phenol-chloroform 
extracted three times and precipitated overnight at -80°C with 95% ice cold ethanol and 
0.3 M sodium acetate.  The low molecular weight DNA was pelleted at 20,000 x g for 10 
min at 4°C, washed in 70% RT ethanol, and resuspended in 15 μl of nuclease-free water.  
Nuclear low molecular weight DNA was prepared by first isolating nuclei from infected 
cells using the Dignam protocol (Dignam et al., 1983).  Pelleted nuclei were treated as a 
cell pellet and the modified Hirt protocol was performed as described above.  
Real time quantitation of viral genomes.  Low molecular weight DNA samples 
prepared for this analysis were spiked with 500 ng pRL-Null plasmid (Promega) directly 
after incubation in Lysis buffer to control for sample loss during the procedure.  Primers 
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were designed using Primer3 software (Rozen and Skaletsky, 2000) to amplify 125- and 
129-bp fragments of the BKV TU NCCR and β-lactamase gene of pRL-Null (Promega), 
respectively.  Primers were synthesized by Invitrogen and the sequences are as follows: 
TUNCCRFOR (5’  CGCCCCTAAAATTCTCTCTT  3’); TUNCCRREV (5’ ATGTCTG 
TCTGGCTGCTTTC  3’); RTAmpFOR (5’  TCGCCGCATACACTATTCTC  3’); 
RTAmpREV (5’  GCCGCAGTGTTATCACTCAT  3’).  Reactions were performed in a 
total volume of 25 μl using Power SYBR Green PCR Master Mix (Applied Biosystems), 
1 μl 1:125 diluted sample, and 300 nM of each primer.  Amplification was performed in 
96-well PCR plates (Bio-Rad) using the iCycler iQ5 Real Time Detection System (Bio-
Rad) with the following PCR program:  2 min at 50°C; 10 min at 95°C; 40 cycles of 
denaturation at 95°C for 15 sec and annealing and extension at 58°C for 1 min.  Results 
are presented as the fold change in BKV genome copy numbers, with the levels in the 
“36 hpi, IFN-γ, Nuc” sample arbitrarily set to one.  Results were normalized to levels of 
pRL-null (internal plasmid control) using the Livak method (Livak and Schmittgen, 
2001).     
Western blotting.  Total cell protein was harvested at the indicated times post-infection 
using EIA lysis buffer (Harlow et al., 1986) supplemented with 5 μg/ml 
phenylmethylsulfonyl fluoride, 5 μg/ml aprotinin, 5 μg/ml leupeptin, 0.05 M sodium 
fluoride, and 0.2 mM sodium orthovanadate.  Samples were electrophoresed, transferred 
to a nitrocellulose membrane, and probed with antibodies as previously described (Abend 
et al., 2007).  The following primary antibodies were used: pAb416 (Harlow et al., 1981) 
for detection of TAg expression, p5G6 (gift of D. Galloway) for detection of VP1 
expression, #9171 (Cell Signaling Technology) for detection of phospho-STAT1 levels, 
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and Ab8245 (Abcam) for detection of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) expression.   
Southern blotting.  Low molecular weight DNA samples were prepared for 
electrophoresis by digestion with EcoRI to linearize the viral genome and DpnI, which 
only cuts methylated sequences, to distinguish input DNA from the replicated genome.  
Samples were electrophoresed on a 1% agarose gel at 100 V and transferred to a 
positively charged nylon membrane (Perkin Elmer) by capillary action overnight in 20x 
SSC (3 M NaCl, 0.3 M sodium citrate dihydrate).  The probe was prepared by digestion 
of pGEM-7-TU with PvuII and isolation of the 3.2 kb fragment corresponding to the 
early coding region.  The Random Primers DNA Labeling System (Invitrogen) was used 
to radiolabel 100 ng of the PvuII fragment with [α-32P]dCTP and 20 ng of probe was 
added to the hybridization buffer (5x SSC, 1% SDS, 1x Denhardt’s solution, 100 μg/ml 
denatured salmon sperm DNA) for incubation overnight at 68°C.  The blot was then 
washed extensively and exposed to film.    
Site-directed mutagenesis and NCCR swap.  The following primers were synthesized 
and HPLC purified (Invitrogen) to introduce bases changes (in bold) that insert restriction 
enzyme sites (underlined) into the BKV genomic clones:  NCCRSpeIFOR (5’  GGGGA 
AATCACTAGTCTTTTGCAATTTTTGCAAAAATGG  3’); TAgPmlIFOR                 
(5’  ACACCACCCCCAAAATAACACGTGCTTAAAAGTGGCTTATAC  3’); 
NCCRSacIIFOR (5’  GACAAGGCCAAGATTCCGCGGCTCGCAAAACATGTC  3’).  
The reverse primers are exactly the reverse complement of the sequences shown.  
Mutagenesis was performed according to the protocol for the Quik Change II Site-
Directed Mutagenesis Kit (Stratagene) using primer pairs at 1.25 nM each, 100 ng of 
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pGEM-7-TU or pBR322-Dik as template, 1 mM dNTPs, and 1.25 U Native Pfu DNA 
polymerase (Stratagene) in 25 μl total reaction volume.  The following two-step PCR 
program was used: 3 min at 95°C, 18 cycles of denaturation at 95°C for 15 sec and 
annealing and extension at 65.5°C for 16 min and 30 sec.  The resulting genomic clones 
were digested with SpeI and SacII and both the plasmid and NCCR fragments were 
isolated by gel extraction.  NCCRs were religated into the opposite genomes and the 
DNA was prepared for transfection as described above.    
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Preliminary Results on the Characterization of IFN-γ-Mediated Regulation  
IFN-γ is a widely known anti-viral cytokine produced primarily by T cells and 
NK cells.  It is a hallmark of the T helper 1 (Th1) phenotype of T cells and overall has 
pro-inflammatory, anti-proliferative, and pro-apoptotic effects on cells.  The IFN-γ 
receptor is expressed on most cell types, including the kidney epithelial cells used in our 
studies.  The signaling cascade is initiated by binding of IFN-γ to its cell surface receptor, 
which results in the phosphorylation of Janus kinase 1 (JAK1) and JAK2, which are 
associated with the cytoplasmic domains of the receptor.  Activated JAK1 and JAK2 then 
phosphorylate the receptor, which allows recruitment and binding of signal transducer 
and activator of transcription 1 (STAT1).  Upon binding the receptor, STAT1 is 
phosphorylated, which promotes dimerization and translocation to the nucleus.  Activated 
STAT1 homodimers act as transcription factors in the nucleus to mediate expression of 
IFN-γ responsive genes (reviewed in Pestka et al., 2004; van Boxel-Dezaire and Stark, 
2007).  
In microarray studies, IFN-γ stimulation has been shown to significantly induce 
the expression of over 100 genes at early times post-treatment, including a number of 
transcription factors such as STAT1, IRF-1, PML, IRF-9, C/EBP, and TEAD4 (Der et al., 
1998).  In addition, IFN-γ signaling promotes the activation of many other factors, 
including STAT3, AP-1, USF-1, NF-κB, IRF-1, IRF-8, ATF-2, GATA-1, CREB, and 
PU.1 (van Boxel-Dezaire and Stark, 2007).  These transcription factors can subsequently 
regulate the expression of other proteins in a second wave of IFN-γ-mediated 
transcription (van Boxel-Dezaire and Stark, 2007).   
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Transcription factors are DNA binding proteins that regulate transcription mainly 
by binding to enhancer regions, recruiting other cellular factors and facilitating the 
formation of a stable transcription initiation complex at the promoter of a gene.  
Transcription factors can also regulate gene expression by binding and recruiting 
chromatin remodeling enzymes, histone acetyltransferases (HATs) and histone 
deacetylases (HDACs, reviewed in Bhaumik et al., 2007; Struhl, 2006).  The N-terminal 
tails of histones contain several lysine residues, which have positive charges that interact 
with the negatively charged backbone of DNA, forming a closed, condensed chromatin 
structure.  HATs transfer acetyl groups (-COCH3) from acetyl-coenzyme A to histone 
lysine residues, resulting in the neutralization of charged histone tails and an opening of 
the chromatin structure.  There are many known HATs, including p300/CBP, P/CAF, 
Gcn5, ACTR, SRC-1, and TAF130/250.  Hyperacetylated histones are typically 
associated with genes that are being actively transcribed.  HDACs are enzymes that 
remove acetyl groups from the lysine residues, resulting in a stronger interaction between 
histones and DNA and subsequently condensing the chromatin.  There are four classes of 
HDACs, with class I (HDAC1, -2, -3, and -8) being the most widely expressed (Adcock, 
2006).  Hypoacetylated histones are usually associated with genes that have been 
silenced.  Histones can also be ubiquitinated, phosphorylated, methylated, and 
sumoylated; all of these modifications can affect chromatin structure by altering the 
interaction between histones and DNA (Bhaumik et al., 2007).   
  In Chapter II, we described the inhibitory effect of IFN-γ on BKV replication, 
mediated primarily at the level of early gene transcription.  The inhibition of TAg 
expression results in repression of viral DNA replication, late gene expression, and 
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progeny production due to the integral role of TAg in the viral life cycle.  We propose 
that there are several mechanisms by which IFN-γ could affect viral replication.  First, it 
is possible that IFN-γ disrupts viral trafficking during entry or delivery of the viral 
genome to the nucleus.  More likely, we hypothesize that IFN-γ signaling has a direct 
effect on transcription initiation by either 1) activating transcriptional repressors that bind 
viral DNA and prevent formation of the transcription initiation complex, 2) activating 
transcription factors that recruit HDACs and facilitate the condensation of the viral 
genome, or 3) activating transcriptional repressors that prevent expression or activation of 
HATs.  In this chapter, we will first present data demonstrating that IFN-γ does not affect 
delivery of the viral genome to the nucleus, suggesting instead a direct effect on 
transcription initiation.  In addition, we will show that the effect of IFN-γ is long-lasting 
and reversible by simultaneous treatment with HDAC inhibitors.  While more studies are 
needed, these results suggest that IFN-γ mediates chromatin remodeling events on the 
BKV minichromosome.    
Results and Discussion 
As stated above, an alternative explanation for the observed effects of IFN-γ on 
BKV replication (see Chapter II) is that IFN-γ signaling inhibits viral trafficking or 
delivery of genomic DNA to the nucleus, the site of viral replication.  To rule out this 
possibility, RPTE cells were infected with BKV and treated with IFN-γ at 3 hours post-
infection (hpi).  Low molecular weight DNA was harvested either from whole cells or 
from isolated nuclei at 36 hpi, approximately when TAg expression is first detectable but 
prior to viral DNA replication, and at 96 hpi, a late stage of infection when viral progeny 
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are being produced and released from cells.  Samples were analyzed in a real time PCR 
assay to quantify the viral genome copies present (Figure 4.1).  At 36 hpi, there was no 
difference in viral genome copy number in the nuclei of untreated and IFN-γ treated cells, 
indicating that IFN-γ has no effect on viral trafficking or DNA delivery to the nucleus.  
As expected, there were more viral genomes present in the whole cell sample than in the 
nuclear sample (compare 36 hpi UN, Total and 36 hpi UN, Nuc), indicating that a 
fraction of viruses had entered the cell but not yet trafficked to the nucleus.  At 96 hpi, 
there was a 9.8-fold decrease in the number of viral genomes present in nuclei of IFN-γ 
treated cells compared to untreated cells.  This result is comparable to our previous 
observations of IFN-γ inhibition of TAg transcript levels and protein expression (Chapter 
II).  Thus, IFN-γ does not appear to affect viral trafficking, but instead mediates an 
inhibitory effect on BKV early region transcription, consequently leading to a decrease in 
gene expression and viral DNA replication. 
Previously, we observed an interesting pattern of viral gene expression in the 
presence of IFN-γ: TAg and VP1 levels peaked at 72 and 84 hpi, respectively, after which 
expression tapered down to a low level.  To examine the extent of this effect, RPTE cells 
were infected, treated with IFN-γ at 3 hpi, and total cell lysates were harvested at 5, 7, 9, 
11, and 13 days post-infection (dpi).  Western blot analysis revealed that this low level of 
viral gene expression was maintained throughout the duration of the experiment, even 
though the cells were only treated once with IFN-γ (Figure 4.2).  We would not expect a 
cytokine to be stable for this length of time in the media, however it is possible that the 
signaling cascade is being activated by the crosstalk between the type I and type II 










Figure 4.1.  IFN-γ does not affect delivery of BKV DNA to the nucleus.  RPTE cells 
were infected with BKV TU at an MOI of 0.5 IU/cell and treated with 250 U/ml IFN-γ at 
three hpi.  Low molecular weight DNA was harvested at 36 or 96 hpi from whole cells 
(Total) or isolated nuclei (Nuc).  Samples were analyzed by real time PCR to determine 
the relative number of BKV genomes in each sample.  Results are presented as fold 
change in BKV genome copy numbers, normalized to the levels of an internal control 
plasmid to account for sample loss during preparation.  Samples were analyzed in 
triplicate and the fold change in BKV genome copies at 36 hpi in the nuclei of cells 













Figure 4.2.  IFN-γ-mediated inhibition of viral gene expression is sustained out to 
late stages of infection.  RPTE cells were infected with BKV TU at an MOI of 0.5 
IU/cell and treated with 50 U/ml IFN-γ at three hpi.  Total cell lysates were harvested at 
5, 7, 9, 11, and 13 dpi.  For each sample, 5 μg of  protein were electrophoresed on an 8% 
SDS-polyacrylamide gel and analyzed by Western blot, probing for TAg, VP1, and 
GAPDH.  Mock, mock-infected samples with no IFN-γ treatment; dpi, days post-
infection. 
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Alternatively, this result may indicate that histones associated with the viral 
minichromosome are being deacetylated, which would reduce viral gene expression and 
may require a positive signal for initiation of HAT activity.  In this scenario, the viral 
genome would appear to be stably repressed in the presence of IFN-γ.  
We next postulated that pretreatment of cells with IFN-γ would induce an anti-
viral state such that viral gene expression would be inhibited from the time of genome 
delivery to the nucleus.  In this experiment, cells were either untreated, treated with IFN-γ 
at 3 hpi, treated at 3 hpi and washed at 24 hpi to remove IFN-γ, pretreated for 24 h with 
no treatment after infection, or pretreated for 24 h with IFN-γ added after infection and 
washed away at 24 hpi.  Total cell lysates were harvested at 5 dpi and analyzed by 
Western blot probing for TAg, VP1, phosphorylated STAT1, and GAPDH (Figure 4.3).  
It appears that any exposure to IFN-γ is sufficient for repression of TAg expression.  
There is a clear difference, however, in the levels of VP1 such that pretreatment appears 
inhibit expression more than treatment at 3 hpi.  Phosphorylated STAT1 levels were 
examined to monitor the activity of the IFN-γ signaling cascade.  Interestingly, the 
samples in which washes were performed to remove IFN-γ from the cells were very 
similar to lysates from unwashed cells, indicating a continued activation of this signaling 
cascade at 5 days post-treatment.  The persistence of the IFN-γ signaling cascade could 
explain the prolonged effect we see on viral gene expression.  
 To determine if IFN-γ regulates BKV through HDAC activity, cells were infected 
and then treated simultaneously at 1 hpi with IFN-γ and either trichostatin A (TSA) or 
sodium butyrate (NaB), two broad-spectrum HDAC inhibitors.  Total cell protein or low 











Figure 4.3.  Pretreatment with IFN-γ results in greater inhibition of gene expression.  
RPTE cells were infected with BKV TU at an MOI of 0.5 IU/cell and treated with 250 
U/ml IFN-γ in the following ways: treated at 3 hpi, treated at 3 hpi and washed at 24 h 
post-treatment, pretreated for 24 h, or pretreated for 24 h, treated again directly after 
infection, and washed at 24 h post-treatment.  Total cell lysates were harvested at 5 dpi 
and 8 μg of protein were electrophoresed on an 8% SDS-polyacrylamide gel and 
analyzed by Western blot, probing for TAg, VP1, phosphorylated STAT1, and GAPDH.  
Mock, mock-infected samples with no IFN-γ treatment; hpi, hours post-infection; dpi, 
days post-infection; IFN-γ 24h pre, pretreated cells for 24 h with IFN-γ; remove 24hpt, 
washed cells at 24 h post-treatment.   
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respectively (Figure 4.4).  TSA treatment alone resulted in increased TAg expression; 
however, in cells treated with both TSA and IFN-γ, the levels of TAg were similar to 
those of untreated cells.  The same result was seen in the Southern blot analysis for viral 
DNA replication, indicating that TSA treatment was able to prevent IFN-γ-mediated 
inhibition of BKV.  These data suggest that histones associated with the viral genome are 
being deacetylated in the presence of IFN-γ.  In contrast, NaB had little effect on TAg 
expression but seemed to strongly inhibit viral DNA replication both in the absence and 
presence of IFN-γ.  TSA is a hydroxamic acid compound with potent activity against 
class I and class II HDACs, while NaB is a short chain fatty acid with a lower potency 
and non-specific inhibitory action against HDACs (Adcock, 2006).  Assuming that TSA 
is acting more specifically on HDACs, these data suggest that IFN-γ inhibition of BKV is 
HDAC-dependent.  Alternatively, NaB appears to mediate a decrease in the levels of 
modified forms of TAg (various higher molecular weight bands seen in untreated and 
TSA-treated lanes, Figure 4.4).  Similar modifications have been shown to regulate SV40 
TAg functions, and could explain the lack of DNA replication. 
 So far, these experiments are only suggestive of chromatin remodeling and do not 
provide information about specific histone modifications or the location of the modified 
histones on the viral genome.  Future studies using electrophoretic mobility shift assays 
(EMSAs) and chromatin immunoprecipitation (ChIP) will reveal these details.  We will 
not pursue the HDAC inhibitor studies any further for several reasons.  First, HDAC 
inhibitors are known to induce cell cycle arrest and apoptosis (Johnstone, 2002; Richon et 
al., 2000), and thus non-specific effects may confound results after prolonged exposure.  













Figure 4.4.  Treatment with HDAC inhibitors restores BKV gene expression and 
replication in the presence of IFN-γ.  RPTE cells were infected with BKV TU at an 
MOI of 0.5 IU/cell and treated with 250 U/ml IFN-γ and/or 1.32 μM trichostatin A (TSA) 
or 5 mM sodium butyrate (NaB) at 1 hpi.  Total cell lysates or low molecular weight 
DNA were harvested at 4 dpi.  To assay for early gene expression, 8 μg of protein were 
electrophoresed on an 8% SDS-polyacrylamide gel and analyzed by Western blot, 
probing for TAg.  To assay for viral DNA replication, low molecular weight DNA 
samples were run on a 1% agarose gel and analyzed by Southern blotting as described in 





signaling events, and that HDAC inhibitors are known to interfere with IFN-γ signaling 
by preventing STAT1 phosphorylation, nuclear translocation and gene regulation 
(Klampfer et al., 2004; Nusinzon and Horvath, 2005).  Although treatment with HDAC 
inhibitors has not affected phosphorylation of STAT1 in our studies (data not shown), we 
only intended to use this approach as a preliminary screen for HDAC activity in the 
presence of IFN-γ. 
The large number of genes activated and regulated by IFN-γ signaling makes it 
difficult to hypothesize what factors are involved in the inhibition of BKV transcription.  
While we postulate that the histone modifications will be located within the NCCR, this 
400 to 500 bp region contains many predicted and proven binding sites for transcription 
factors that could recruit HDACs or other modifying enzymes.  Our immediate plans 
involve performing EMSAs with short overlapping probes of the NCCR to map the 
regions of DNA that bind additional proteins when incubated with nuclear extracts from 
IFN-γ treated cells.  Then, targeted sequence analysis and supershift assays with specific 
antibodies should allow us to identify the factors involved in the regulation.  
Concurrently, we will determine the type and location of histone modifications in the 
presence of IFN-γ using ChIP.  Immunoprecipitation with antibodies for specific 
modified histone residues will indicate the type of modification, while PCR for specific 
regions of the genome will map the location of the modified histones.  These approaches 
will also allow us to examine other modifications of viral DNA-associated histones, such 
as methylation, phosphorylation, and ubiquitination.  
Chromatin remodeling has been reported as a means to regulate transcription and 
replication in a number of viral systems.  For example, the latent and lytic states of herpes 
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simplex virus are controlled by remodeling of the viral chromatin (Knipe and Cliffe, 
2008).  For HIV, histone deacetylation at the LTR is responsible for restriction of Tat 
expression and transactivation, and thus establishement of latency (Lusic et al., 2003; 
Treand et al., 2006).  The acetylation of histones associated with the SV40 genome has 
been studied in detail, and appears to play a role in the transition from early to late gene 
expression (Balakrishnan and Milavetz, 2006; Balakrishnan and Milavetz, 2007).  We are 
interested in the ability of cytokine-mediated signaling to induce chromatin remodeling 
on the viral genome.  We expect that IFN-γ signaling represses BKV gene expression 
through HDAC activity, making the viral genome less accessible to transcription 
initiation complexes.  In our studies, however, viral gene expression was never 
completely shut off; there was always a low level of TAg and VP1 expression which 
could sustain the infection.  This could explain the ability of BKV to maintain a persistent 
infection in the host, with minimal gene expression to avoid detection by the immune 
response.  The reduction in IFN-γ levels by immunosuppression could then allow the 
viral minichromosome to be opened and transcribed.  It is possible that a positive signal 
is required for the activation and recruitment of HATs to the viral genome, which would 
fit with the increasingly complex set of risk factors for BKV reactivation in 
immunosuppressed patients.    
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Preliminary Results on Archetype BK Virus Replication in a Tissue Culture System 
There are two major types of BKV strains, archetype and rearranged, 
distinguished from each other by NCCR structure.  In archetype strains, the NCCR is 
divided into five blocks of DNA sequences arbitrarily designated O, P, Q, R, and S 
(Markowitz and Dynan, 1988; Rubinstein et al., 1987; Sundsfjord et al., 1994).  The O 
block contains the origin of replication and the TAg binding sites, while the other blocks 
contain many transcription factor binding sites and were defined by the apparent ability 
to move together during NCCR rearrangements.  The rearranged strains have NCCR 
structures that contain partial or full duplications or deletions of these blocks.  
Rearranged BKV strain NCCRs always have O and S blocks and at least one P block, but 
the Q and R blocks are frequently deleted and additional P blocks are often present 
(Cubitt, 2006; Johnsen et al., 1995; Moens and Rekvig, 2001; Moens and Van Ghelue, 
2005).    
It was previously shown that the archetype BKV strains are functionally different 
from the rearranged strains.  Archetype viruses are more efficient at transforming rodent 
cells than rearranged viruses, while rearranged strains are far more efficient at replication 
in tissue culture (Watanabe and Yoshiike, 1982; Watanabe and Yoshiike, 1986).  Several 
groups have tried to propagate archetype BKV in tissue culture by infection of cells with 
clinical samples or transfection of viral genomic DNA.  In each case, the result was either 
no viral replication or replication with concurrent NCCR rearrangements, indicating 
contamination of the clinical sample with rearranged virus or, in the case of transfected 
DNA, the derivation of a rearranged strain from the archetype genome (Rinaldo et al., 
2005; Rubinstein et al., 1991; Sundsfjord et al., 1994; Sundsfjord et al., 1990).  
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Interestingly, the archetype strains are by far the most common BKV strains isolated 
from clinical samples, both urine and blood of healthy and immunocompromised 
individuals (Gosert et al., 2008; Markowitz et al., 1991; Negrini et al., 1991; Sharma et 
al., 2007; Sugimoto et al., 1989; Sundsfjord et al., 1999; Takasaka et al., 2004; ter 
Schegget et al., 1985).  These observations suggest that the archetype strains are not at all 
defective at replication, but that the appropriate conditions for their propagation have not 
been attained in tissue culture systems.    
Previous studies using in vitro reporter assays have demonstrated that the 
archetype early promoter has lower transcriptional activity than rearranged early 
promoters (Gosert et al., 2008; Markowitz and Dynan, 1988; Markowitz et al., 1990).  
Furthermore, BKV promoters with duplications of only the P block have higher 
transcriptional activity (Chakraborty and Das, 1989; Deyerle and Subramani, 1988).  This 
result could be explained by either the presence of important transcription activator 
binding sites within the P block, or by the creation of new transcription factor binding 
sites at the junctions of duplicated blocks.  The archetype promoter is not inhibitory to 
transcription initiation; when short P block fragments from a rearranged NCCR were 
inserted into an archetype NCCR, the resulting promoter had enhanced transcriptional 
activity suggesting the absence of inhibitory elements (Markowitz et al., 1990).  
Although functional for transcription, the lower activity of the archetype early promoter 
could result in minimal expression of TAg and thus impede the progression of the viral 
life cycle.       
 In the second part of this chapter, we begin to explore some of the factors that 
could be required for archetype BKV propagation.  We first propose that the cell types 
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used thus far are simply not supportive of archetype replication and therefore attempt to 
productively infect RPTE cells.  We also consider the possibility that the archetype 
genome is somehow more prone to HDAC activity, resulting in the immediate 
condensation of the viral genome upon entry into a cell and complete repression of viral 
gene expression.  To systematically narrow in on the genomic region that confers the 
ability of a BKV strain to replicate, we produced chimeric genomes in which the NCCR 
from an archetype strain was replaced with the NCCR from a rearranged strain.  The 
NCCR swap allowed viral DNA replication of an otherwise archetype genome.  Next we 
examined the functional relevance of the NCCR swap by cotransfecting the archetype 
genome with a TAg expression plasmid, and again observed viral DNA replication.  
These results provide information about the conditions in the host that promote archetype 
BKV strains to replicate.  
Results and Discussion 
As mentioned above, propagation of archetype BKV has been attempted in 
several common cell lines, including HUVEC-C, a human umbilical vein endothelial cell 
line (Rinaldo et al., 2005); Vero, an African green monkey kidney epithelial cell line 
(Sundsfjord et al., 1990); and HEK, a human embryonic kidney cell line (Rubinstein et 
al., 1991; Sundsfjord et al., 1990).  We first wondered if archetype BKV would replicate 
in a more relevant cell type, such as the primary RPTE cells characterized by our lab 
(Low et al., 2004).  These cells are major sites of BKV lytic infection in the host during 
reactivation and PVN, and thus it seemed likely they would readily support archetype 
replication.  RPTE cells were transfected with viral DNA from either a rearranged strain, 
BKV TU, or an archetype strain, BKV Dik, and viral lysates were harvested at 10 days 
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post-transfection (dpt).  The lysates were then used to infect fresh RPTE cells, which 
were fixed at 4 dpi and analyzed for TAg expression by immunofluorescence to assay for 
the presence of infectious viral progeny in the transfection lysates (Figure 4.5).  
Transfection with the BKV TU genome produced abundant viral progeny, as shown by 
the numerous TAg positive cells upon infection.  Lysates harvested from cells transfected 
with the archetype genome, however, contained no infectious viral progeny, as indicated 
by the absence of TAg expressing cells upon infection.  The epitope  recognized by the 
monoclonal antibody used in the immunofluorescence assay (WEQ/SWW; Lindner et al., 
1998; amino acids 91-95 of TAg), is intact in the TAg sequence of archetype virus, thus 
these results cannot be explained by an inability of the antibody to recognize infected 
cells.  It is possible, however, that infectious progeny were produced, but that the level of 
TAg expression upon infection was below the limit of detection of the assay.  These 
results suggest that additional factors are required to drive archetype BKV replication in 
RPTE cells.   
We next wanted to systematically investigate whether different genomic regions 
affected the ability of BKV strains to replicate.  Using site-directed mutagenesis, we 
inserted unique restriction enzyme sites into archetype and rearranged genomic clones 
such that the NCCR was flanked by SpeI and SacII sites, and the early coding region was 
flanked by SpeI and PmlI sites (Figure 4.6A).  These three sites will allow us to swap the 
three major regions of the genome between archetype and rearranged strains.   
We began our analysis by swapping the region most likely to affect replication: 









Figure 4.5.  Archetype BKV does not productively infect RPTE cells.  RPTE cells 
were transfected with rearranged (BKV strain TU) or archetype (BKV strain Dik) 
genomic DNA and viral lysates were harvested at 10 dpt.  Lysates were subjected to three 
freeze (-80°C)/thaw (37°C) cycles and used to infect fresh RPTE cells.  At 4 dpi, cells 
were fixed and assayed by immunofluorescence for TAg expression, as described in 
(Abend et al., 2007).  Top panels, brightfield.  Bottom panels, FITC channel.  
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NCCR; TU/ArchN, TU genome with archetype NCCR) were transfected into RPTE cells 
alongside the original archetype and rearranged genomes.  Low molecular weight DNA 
was harvested at 4 dpt, digested with DpnI, and analyzed by Southern blot to detect 
replication of viral DNA (Figure 4.6B).  In agreement with previous results, we were 
unable to detect replication of the archetype DNA.  The chimeric archetype genome, 
Arch/TUN, however, replicated robustly in RPTE cells, suggesting that the NCCR is 
responsible for the block of archetype BKV replication.  Similarly, the BKV TU genome 
was efficient at DNA replication, while the sample harvested from transfection of the 
chimeric rearranged genome, TU/ArchN, contained no DpnI-resistant DNA, indicating a 
lack of viral genome replication.  Overall, these results suggest that the NCCR plays an 
important role in regulating BKV replication.  Future studies will address whether the 
replication of the chimeric archetype genome, Arch/TUN, is accompanied by expression 
of viral proteins and production of infectious virions.  In addition, the remaining 
combinations of chimeric genomes will be constructed and analyzed for the ability to 
replicate in RPTE cells.  
  Based on these results, we hypothesized that TAg expression is a limiting factor 
for archetype BKV replication.  The archetype early promoter has lower activity than 
rearranged early promoters and replacement of the archetype NCCR with the higher 
activity BKV TU NCCR induced viral DNA replication, suggesting that higher levels of 
TAg could rescue replication of archetype strains.  To examine the effect of TAg 
expression on archetype replication, we cotransfected archetype or BKV TU genomic 





Figure 4.6.  Rearranged NCCR can promote archetype BKV DNA replication.  A) 
Cloning strategy for genomic region swaps.  B) RPTE cells were transfected with the 
four plasmids from part (A).  Low molecular weight DNA was harvested at 4 dpt and 
assayed by Southern blot for viral DNA replication, as described in Materials and 
Methods.  Arch, archetype BKV; Arch/TUN, archetype genome with TU NCCR; 
TU/ArchN, TU genome with archetype NCCR; hpi, hours post-infection; dpt, days post-
transfection; UN, untreated; Mock, no transfection. 
 122
 and 7 dpt, digested with DpnI, and analyzed by Southern blot to detect replication of 
viral DNA (Figure 4.7).  BKV TU DNA appears to replicate equally as well in the 
absence or presence of the TAg expression plasmid.  The archetype genome, however, 
only replicates in the presence of TAg overexpression, indicating that elevated levels of 
TAg can drive archetype infection.  The levels of replicated archetype DNA decreased at 
7 dpt, most likely due to the limited duration of TAg expression with transient 
transfection.  In addition, the diminished intensities of the DpnI digested bands at 7 dpt 
were likely a result of cell-mediated degradation of foreign DNA.   
These results support the hypothesis that TAg levels are a limiting factor for 
archetype replication.  In addition to providing insight into the requirements for 
productive BKV infection, these data will aide in the development of a tissue culture 
system to propagate archetype BKV strains.  Future plans include using a cell line stably 
transformed with TAg to attempt to propagate and study archetype virus during a 
productive infection.  Finally, our findings provide support for a model of BKV 
reactivation proposed in Chapter V (Figure 5.1), in which rearrangement of the NCCR 
precedes reactivation of archetype BKV.  The rearranged NCCR is required to provide 
higher levels of TAg expression, which promotes the replication of archetype virus.  
These and future experiments will help us to better understand the process of archetype 










Figure 4.7.  Ectopic expression of TAg can facilitate archetype BKV replication.  
RPTE cells were transfected with the rearranged (TU) or archetype (Arch) genomic 
clones, or cotransfected with a TAg expression plasmid.  Low molecular weight DNA 
was harvested at 4 or 7 dpt and assayed by Southern blot for viral DNA replication, as 
described in Materials and Methods.  Mock, no transfection; dpt, days post-transfection; 
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Summary of Results 
BK virus (BKV) is a ubiquitous human pathogen, infecting nearly the entire 
population early in childhood and persisting throughout the lifetime of the host.  In 
healthy individuals, BKV infection does not cause disease although viral shedding in the 
urine is evident periodically.  BKV is widely accepted as the causative agent of 
polyomavirus nephropathy (PVN) in renal transplant recipients and late-onset 
hemorrhagic cystitis (HC) in bone marrow transplant recipients.  The increasing 
prevalence of these BKV-associated diseases in immunosuppressed patients is likely a 
result of more potent immunosuppressive therapies, which may eliminate components of 
the immune system that are necessary to keep the virus in a subclinical state.  We 
hypothesized that cytokines and cytokine-mediated signaling events are important for 
regulating BKV replication, and that the loss of cytokine-producing lymphocytes during 
immunosuppression allows BKV lytic infection to occur.  This dissertation describes our 





In Chapter II, after screening a panel of cytokines and chemokines, we identified 
IFN-γ as having a strong inhibitory effect on BKV early and late gene expression in a 
dose-dependent manner.  In IFN-γ treated cells, we detected significant reductions in 
TAg transcripts at four days post-infection, suggesting that IFN-γ-mediated inhibition 
was occurring at the level of transcription.  IFN-γ did not appear to change the kinetics of 
viral gene expression, but treatment of infected cells resulted in a significant decrease in 
viral progeny production.  Finally, we demonstrated that the effect of IFN-γ was similar 
for three different strains of BKV, suggesting that this cytokine is relevant for the 
regulation of all BKV strains.   
In Chapter III, we investigated the effect of TGF-β, a cytokine that is stimulated 
by certain immunosuppressive therapies, on BKV lytic infection.  Viral gene expression, 
and specifically the activity of the BKV early promoter, was regulated by TGF-β in a 
strain-dependent manner.  The TU strain of BKV had enhanced early promoter activity in 
the presence of TGF-β, while the Dik, Dunlop, and Proto-2 strains were either unaffected 
or had decreased promoter activity, depending on the cell type examined.  Using site-
directed mutagenesis, we identified a small segment of the TU promoter that is required 
for stimulation of activity in response to TGF-β.  While these data suggest that TGF-β 
may play a role in BKV reactivation, perhaps more importantly the results demonstrate 
that BKV strains can respond differently to cytokine treatment. 
We are primarily interested in the process of BKV reactivation in kidney 
epithelial cells, leading to the development of PVN in renal transplant recipients.  The 
primary human renal proximal tubule epithelial (RPTE) cell culture system established 
by our lab (Low et al., 2004) is well suited to examine BKV replication in this context.  
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As discussed in Chapter I, we hypothesized based on clinical observations that cytokines 
regulate BKV during persistence in healthy individuals, and their differential expression 
in transplant patients facilitates reactivation.  Our studies of IFN-γ- and TGF-β-mediated 
regulation are highly relevant and complementary.  The primary targets of 
immunosuppressive agents are lymphocytes; most immunosuppression regimens include 
calcineurin inhibitors, antiproliferative agents, and/or corticosteriods to block the 
replication and activation of T cells and B cells.  T cells, especially CD4+ T helper 1 cells 
and CD8+ cytotoxic T lymphocytes (CTLs), are major producers of IFN-γ and therefore 
levels of IFN-γ are reduced during immunosuppression.  Concurrently, TGF-β expression 
is enhanced in renal proximal tubular epithelial cells by certain immunosuppressive drugs 
(Khanna et al., 1999a; Khanna et al., 1999b; McMorrow et al., 2005; Shihab et al., 1996).  
In addition, TGF-β is itself immunosuppressive and the signaling cascades of TGF-β and 
IFN-γ are antagonistic (Giannopoulou et al., 2006; Ulloa et al., 1999).  Given our results 
that IFN-γ inhibits BKV replication and TGF-β enhances replication of certain BKV 
strains, we could hypothesize that immunosuppression creates a cytokine environment 
that is ideal for BKV reactivation.   
Our observation that the TGF-β effect is strain-dependent, however, complicates 
this hypothesis.  There are no data suggesting that specific rearranged strains are 
associated with enhanced pathogenesis, although NCCR rearrangements in general may 
be (Gosert et al., 2008).  We were able to map the TGF-β-responsive elements in the TU 
strain; although we were unable to find any other strain with a predicted ZEB-1 binding 
site, a number of strains contain putative Smad3 binding sites (listed in Chapater III).  
Therefore, it is possible that additional TGF-β-responsive elements exist in other strains, 
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as Smad3 has many documented binding partners (Brown et al., 2007; Feng and Derynck, 
2005).  Furthermore, the effects of TGF-β are known to be different for epithelial cells, 
fibroblasts, and immune cells (Li et al., 2006; Rahimi and Leof, 2007); thus the use of 
these cell types in our assays may reveal other TGF-β regulated strains of BKV.  In 
particular, likely candidates for such experiments include lymphocytes, which may play a 
role in the dissemination of BKV during primary infection (Doerries et al., 1994), and 
bladder epithelial cells, which are the sites of viral lytic replication during HC.     
Finally, it is possible that the importance of TGF-β for BKV reactivation stems 
from the immunosuppressive and anti-inflammatory effects of this cytokine.  
Specifically, TGF-β inhibits the proliferation and differentiation of naïve T cells into 
effector cells, CTLs and T helper cells (Gorelik and Flavell, 2002; Li et al., 2006), 
thereby inhibiting expression of IFN-γ.  In this scenario, the relevance of TGF-β 
signaling in BKV reactivation is indirect: a block in the production of IFN-γ would 
alleviate the repression of viral replication, but there is no direct regulation of promoter 
activity by TGF-β signaling components.  In addition, TGF-β, in conjunction with IL-6, 
stimulates the development of T helper 17 cells, named for their ability to produce 
members of the IL-17 family of proinflammatory cytokines (Bettelli et al., 2008; 
Steinman, 2007; Tato and O'Shea, 2006).  In particular, IL-17 has been implicated in 
immune-mediated tissue injury.  Given that immunosuppression alone is not sufficient to 
cause PVN, and instead it appears that some renal tissue damage may also be required, 
IL-17 expression and signaling events may play a role in BKV reactivation and disease.   
The best way to investigate hypotheses involving the regulation of immune cells 
and their effects is to use a small animal model for BKV persistence and reactivation.  
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Our lab has made several attempts to develop such a model.  First, we tried to establish a 
mouse model of PVN using K virus, a murine polyomavirus that is genetically more 
similar to BKV than mouse polyomavirus (Py), most notably because it does not encode 
a middle T antigen (Imperiale and Major, 2007).  Although previous reports describe the 
establishment of a persistent K virus infection in kidney epithelial cells of mice, we were 
unable to reproduce these results.  Next, we collaborated with a lab interested in 
identifying the block to BKV replication in rodent cells, which may allow the subsequent 
development of a transgenic mouse that supports BKV lytic replication.  This work has 
not yet revealed a cellular factor that confers permissiveness of rodent cells to productive 
BKV infection.  Recently, a mouse model for PVN using Py was reported: mice 
underwent renal transplantation followed by infection with Py, and the characteristics and 
effects of viral replication were examined (Han Lee et al., 2006).  Although this model 
demonstrated preferential Py replication in the graft resulting in accelerated graft failure, 
it did not incorporate a persistent infection prior to transplantation.  In addition, the 
significant genetic differences between Py and BKV limit the usefulness of this system, 
as only questions about the host response to viral reactivation could be addressed.  
Establishment of an accurate small animal model for PVN would be extremely valuable 
for the study of BKV replication and the immune system during reactivation. 
  In Chapter IV, we described the preliminary results from two current areas of 
research.  First, we have continued to investigate the regulation of BKV by IFN-γ-
mediated signaling events, as this cytokine has inhibitory effects on all viral strains 
examined and thus is relevant for an overall understanding of the immune response to 
BKV.  We demonstrate that IFN-γ does not affect viral trafficking or delivery of the 
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genome to the nucleus, which further supports regulation at the level of transcription.  
The inhibition appears to be long-lasting, effective to at least nine days post-infection, 
and is stronger if cells are treated with IFN-γ prior to infection.  Pretreatment may cause 
the cells to adopt an antiviral state in which the factors that regulate BKV are activated 
and recruited to the nucleus even before infection; thus, when viral DNA enters the 
nucleus it is immediately repressed.  We hypothesized that IFN-γ signaling results in a 
stable chromatin remodeling event that drives the viral genome into a closed 
conformation.  Treatment of infected cells with broad spectrum histone deacetylase 
(HDAC) inhibitors restores viral gene expression and replication in the presence of IFN-
γ, supporting this hypothesis.   
The second area of research described in Chapter IV is aimed at identifying the 
factors required for archetype BKV strains to replicate in tissue culture.  While we were 
optimistic that RPTE cells, the model system developed by our lab to mimic BKV lytic 
infection in the kidney, would support archetype replication, there was no indication of 
infectious progeny production or viral DNA replication in our assays.  Instead, we began 
a systematic approach to identify the region of the archetype genome that is responsible 
for viral inactivity.  By inserting unique restriction enzyme sites flanking the NCCR and 
the early coding region, we can exchange genomic fragments between the rearranged TU 
strain and the archetype Dik strain.  Substitution of the rearranged NCCR into the 
archetype genomic clone promoted robust viral DNA replication.  Furthermore, 
cotransfection of the archetype genome with a TAg expression plasmid also allowed 
replication of viral DNA.  These findings suggest that the promoter activity of the NCCR 
determines the ability of a viral strain to replicate in tissue culture.  We further 
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hypothesized that the NCCRs of rearranged and archetype strains may differ in chromatin 
structure, resulting in a difference in promoter activity.  Thus, the preliminary results 
from both areas of research in Chapter IV will lead to a deeper investigation of chromatin 
remodeling events in the context of viral infection.  
 
Major Questions in the Study of BKV Reactivation 
There are at least four critical questions that must be addressed to further our 
understanding of BKV reactivation and associated disease in the context of 
immunosuppression: 
1) What factors or conditions allow archetype BKV to replicate in the host but not in 
a tissue culture system?  
2) What is the pathological relevance of the archetype and rearranged BKV strains? 
3) Why are the archetype strains preferentially shed in the urine, while the 
rearranged strains are preferentially found in the blood? 
4) Ultimately, what are the factors that drive BKV reactivation in kidney transplant 
patients? 
We will discuss these questions in greater detail in the following paragraphs. 
 
What factors or conditions allow archetype BKV to replicate in the host but not in a 
tissue culture system?  As described in Chapters I and IV, there have been many studies 
demonstrating that archetype BKV strains do not replicate in tissue culture systems 
(Rinaldo et al., 2005; Rubinstein et al., 1991; Sundsfjord et al., 1994; Sundsfjord et al., 
1990; Watanabe and Yoshiike, 1982; Watanabe and Yoshiike, 1986).  In the human host, 
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however, these viruses replicate quite efficiently, since the vast majority of clinical 
isolates, both from healthy individuals and immunosuppressed patients, have archetype 
NCCR structures (Gosert et al., 2008; Markowitz et al., 1991; Negrini et al., 1991; 
Sharma et al., 2007; Sugimoto et al., 1989; Sundsfjord et al., 1999; Takasaka et al., 2004; 
ter Schegget et al., 1985).  Based on these observations, it appears that archetype BKV 
strains are in no way defective at replication, and instead we can propose that there are 
either factors missing that may direct propagation or inhibitory factors present that are 
preventing it. 
The simplest explanation for these observations is that archetype BKV is only 
able to productively infect very specific cell types in the host, and that these cells have 
not yet been used for propagation studies.  Other viruses have demonstrated such 
specificity, notably human papillomaviruses, which replicate in stratified squamous 
epithelium in the host and rely on differentiation of the cells for progression through the 
viral life cycle (Howley and Lowy, 2007).  It was not until the development of complex 
raft cultures that researchers were finally able to study and propagate papillomaviruses in 
a cell culture system (Asselineau and Pruniera, 1984; McCance et al., 1988).  The 
restriction of archetype BKV replication is not related to entry or trafficking, since 
transfection of viral DNA does not allow propagation (see Chapter IV; Rinaldo et al., 
2005; Rubinstein et al., 1991).  Instead, this restriction is likely the result of differential 
expression of transcription factors that regulate viral early gene expression.  Host cell 
restriction by transcription factor expression has been suggested for JC virus (JCV), for 
which productive infection of rearranged strains appears to be limited to cells that express 
high levels of NF-1/X (Messam et al., 2003; Monaco et al., 2001).  Similarly, expression 
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of a specific transcription factor may also regulate archetype BKV replication, and the 
permissive cell types have simply not yet been examined.   
One promising candidate cell type for susceptibility to archetype strains is 
primary bladder epithelial cells.  BKV sequences have been detected in normal and 
neoplastic bladder epithelium (Monini et al., 1995).  Furthermore, the association of BKV 
with HC, a bladder infection, and the prevalence of virus in urine samples from healthy 
and immunosuppressed individuals suggest susceptibility of these cells to infection.  We 
are currently investigating whether primary bladder epithelial cells will support 
productive archetype BKV infection.  However, the bladder and ureter are lined with 
transitional epithelium, layers of epithelial cells not unlike stratified squamous 
epithelium, which allow the bladder to contract and expand.  It is possible that archetype 
BKV will require a more complicated cell culture system, like that of human 
papillomavirus, to efficiently replicate.    
Alternatively, it is possible and perhaps more likely that archetype strains require 
a positive factor to initiate replication, one that persistently infected cells are exposed to 
only during certain conditions.  For example, it has been shown that the S block of the 
NCCR contains steroid hormone response elements and treatment of BKV-infected cells 
with glucocorticoids, estrogen, or progesterone results in higher viral yields (Moens et al., 
1994).  A hormone-dependent enhancement of viral replication would be relevant for 
reactivation in kidney and bone marrow transplant patients, who are often treated with 
corticosteroids as a part of their immunosuppressive regimen.  There is some evidence 
suggesting that corticosteroid therapies are associated with an increased risk for BKV 
reactivation and PVN (Hirsch et al., 2002; Trofe et al., 2003).  In addition, progesterone-
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mediated enhancement of viral replication may be relevant to regulation of BKV during 
pregnancy.  Viral shedding is more prevalent in pregnant women compared to the general 
population, particularly in the second and third trimesters when the levels of progesterone 
peak (Bendiksen et al., 2000; Boldorini et al., 2008; Coleman et al., 1980; Markowitz et 
al., 1991).  Thus, steriod hormones may be positive factors that stimulate cells to be 
permissive to archetype BKV replication.   
Another possible factor required for propagation of archetype strains may be 
elevated levels of TAg expression.  As previously discussed (Chapter I and Chapter IV), 
archetype strains are known to have lower early promoter activity than rearranged strains.  
It is possible that these viruses do not produce enough TAg to facilitate viral DNA 
replication.  JCV archetype and rearranged strains have characteristics very similar to 
those described for BKV (reviewed in Yogo and Sugimoto, 2001).  Propagation of JCV 
archetype strains has been demonstrated in cells ectopically expressing JCV TAg (Sock 
et al., 1996) and COS-7 cells, which stably express SV40 TAg (Hara et al., 1998), 
without the induction of NCCR rearrangements.  Based on our preliminary results in 
Chapter IV, it is likely that the same will be true for archetype BKV, however, further 
studies are needed to demonstrate progeny production and stability of the NCCR.   
As proposed in Chapter IV, there may be differences in viral chromatin structure 
that could explain the ability of rearranged strains to replicate more efficiently than 
archetype strains.  For example, the archetype NCCR may contain more or higher affinity 
binding sites for transcription factors that recruit HDACs, leading to condensation of the 
genome and restriction of transcription and replication.  Conversely, rearranged NCCRs 
may have additional binding sites that aide in the recruitment of histone 
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acetyltransferases (HATs), leading to an open chromatin structure that promotes 
transcription and replication.  In either case, the positive factor required for archetype 
replication could be one that inhibits HDAC (or stimulates HAT) activity or recruitment.  
Many signaling cascades, including those activated in response to cytokines, could be 
responsible for such an effect by activating or inducing the appropriate transcription 
factors.  However, treating cells with HDAC inhibitors may allow efficient propagation 
of archetype virus, and the subsequent study of BKV minichromosome structures and 
factors that participate in regulation under different conditions.   
 
What is the pathological relevance of the archetype and rearranged BKV strains?  
For JCV, the pathological relevance of NCCR structure is quite clear.  JCV is the 
causative agent of progressive multifocal leukoencephalopathy (PML), a fatal 
demyelinating disease that affects severely immunosuppressed individuals (reviewed in 
Khalili et al., 2006).  Viral genomes containing promoter regions with a conserved linear 
structure, designated archetype, are primarily isolated from urine samples, kidney, and 
tonsillar tissues of healthy individuals (Agostini et al., 1996; Jeong et al., 2004; Kato et 
al., 2004; Tominaga et al., 1992; Yogo et al., 1990).  Viral genomes with NCCR 
rearrangements, deletions, or amplifications are isolated routinely from the brains of 
PML patients and are designated PML-type strains (Loeber and Doerries, 1988; Martin et 
al., 1985).  Furthermore, PML-type strains only replicate efficiently in human glial cells, 
the site of lytic infection and disease, and stromal cells and B lymphocytes, which likely 
aide in viral dissemination to the brain (Imperiale and Major, 2007).  Thus, NCCR 
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rearrangements are highly associated with JCV lytic infection in the brain and 
progression to PML.     
Based on the similarities between BKV and JCV, we would predict that NCCR 
rearrangements in BKV NCCRs would also correlate with disease progression.  
However, the fact that BKV both causes disease and maintains persistence at the same 
sites in the host, the kidney and bladder epithelium, creates difficulty in distinguishing 
strains associated with disease from those associated with persistence and transmission.  
In a recent report, Gosert et al. (2008) made several important observations.  First, 
rearranged strains were more frequently detected in the plasma than in the urine, although 
archetype strains still predominated in both.  Second, patients with rearranged BKV had 
significantly higher viral loads in the blood.  Finally, among patients that had progressed 
to PVN, those with rearranged BKV had more inflammation and more extensive cell 
damage than patients with archetype BKV, as determined by examination of kidney 
biopsies.  This is the first study to correlate BKV NCCR rearrangement with more severe 
disease in kidney transplant patients.   
While it is possible that certain conditions of the host could predispose archetype 
BKV to acquire NCCR rearrangements, it seems likely that the changes occur randomly 
and sporadically, especially since rearrangements have been inconsistently observed in 
parallel cultures in vitro (Rinaldo et al., 2005).  The functional relevance of the 
rearrangement might be very general: the resulting viral promoter is more active for early 
region transcription, resulting in more DNA replication and progeny production.  The 
higher viral loads then lead to greater cell damage and more severe disease.  In 
immunocompetent individuals, robust expression of viral antigens could lead to early 
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detection by the immune response and elimination of virus-infected cells before progeny 
production.  Thus, in healthy individuals, rearranged strains may be at a disadvantage due 
to activation of the immune response, while archetype strains may be more adept at 
immune avoidance, and thus persistence and replication.   
In contrast, it is possible that NCCR rearrangements change the cell tropism of the 
virus.  This would explain the difficulty in propagating the archetype strains in the same 
cells that support replication of rearranged strains.  Alternatively, NCCR rearrangements 
might change the way the virus is regulated in response to cytokine-mediated signaling or 
other factors.  As suggested in Chapter III, the presence or absence of transcription factor 
binding sites can result in differential regulation of viral promoters in the presence of 
cytokines.  There is one report suggesting that BKV strains containing a mutated Sp1 
binding site are associated with development of hemorrhagic cystitis in bone marrow 
transplant recipients (Priftakis et al., 2001).  Gosert et al. (2008), however, did not report 
any NCCR rearrangements or binding sites that were common among the isolates from 
the blood of PVN patients.  While differential regulation by cytokines is an appealing 
idea, it is not yet supported by clinical data.   
It is important to restate that the majority of BKV sequences in clinical samples 
have archetype NCCR structures.  Gosert et al. (2008) report that 85 and 92% of 
sequences in the blood and urine, respectively, were archetype BKV and that 
approximately 50% of the patients that developed PVN were infected with archetype 
strains.  These data argue against a clinical relevance for NCCR rearrangements, as it is 
clear that the replication of archetype strains can result in disease.  Instead, perhaps 
rearranged NCCRs facilitate the replication of archetype strains by providing higher 
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levels of TAg expression in trans (as discussed above).  If NCCR rearrangements are 
random events, it should be possible to have genomes with changes in the coding regions 
as well.  Thus, in addition to the functional NCCR rearranged strains, there could also be 
non-functional genomes with coding region rearrangements that disrupt viral gene 
expression and are defective for replication.  One could then envision a population of 
viral genomes with highly active rearranged NCCRs and disruptions to the late coding 
region.  These genomes would express high levels of TAg but no late proteins, and 
therefore would be defective for replication themselves; however, the expression of TAg 
from these ‘helper’ viruses could facilitate archetype BKV replication.  In this scenario, 
rearrangements in the NCCR may be indirectly essential for archetype BKV persistence 
and reactivation. 
 
Why are the archetype strains preferentially shed in the urine, while the rearranged 
strains are preferentially found in the blood?  This question is perhaps a bit 
misleading: archetype strains of BKV are actually the most common strains found in both 
blood and urine samples, as described above and in Chapter I.  Interestingly, Gosert et al. 
(2008) observed that the viral load of archetype BKV in the urine was significantly 
higher than that of rearranged BKV, while the opposite was true in the blood.  We can 
propose two different explanations for this observation: either the two types of virus are 
replicating in different cells or the progeny are being released in different ways.   
Based on the inability to propagate archetype strains in cells that are highly 
susceptible to infection with rearranged BKV, it is possible that the two types of virus 
exhibit different cell tropisms (this idea has been discussed in the sections above).  It is 
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necessary to assume, however, that archetype BKV can readily infect kidney epithelial 
cells, although it may require specific conditions to productively replicate.  Archetype 
strains are thought to be the transmitted form of BKV, and the derivation of rearranged 
strains from archetype genomes has been demonstrated.  Therefore, archetype virus must 
be capable of establishing persistence in the kidney.  If archetype strains are also able to 
infect additional cell types, such as primary bladder epithelial cells, then simultaneous 
infection of kidney and bladder epithelial cells could allow archetype progeny to be 
released into the blood and urine.  If rearranged strains can only infect the kidney 
epithelium, then viral progeny may be channeled primarily into the blood. 
The alternative explanation is that there is a difference in the release of archetype 
and rearranged progeny from the cell.  Very little is known about how polyomaviruses 
exit the infected cell, but there are reports describing both lytic bursts and viral egress 
from intact cells (Imperiale and Major, 2007).  Although there has been no direct 
comparison made between the replication kinetics of archetype and rearranged virus in 
the host, the behavior of these two viruses in tissue culture suggests that archetype BKV 
has a slow replication cycle and rearranged strains replicate quickly and robustly.  
Perhaps this rapid production of rearranged BKV progeny overwhelms the normal viral 
egress pathway and instead virions are released by a lytic burst.  The destruction of 
epithelial cells may help the virus spread and infect surrounding cells, including the 
endothelial cells of nearby blood vessels.  Replication in and subsequent lysis of these 
cells could release the virus into the bloodstream.  In contrast, the slower replication of 
archetype strains could promote viral egress, leaving infected cells intact and perhaps 
favoring release of virus in the urine instead of the bloodstream.  The presence of 
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archetype virus in the blood of immunocompromised patients with PVN may indicate 
that extensive and unregulated replication is also possible with archetype strains and will 
result in cell lysis.  
 Differences in viral release could also be mediated by mechanisms of egress.  
Epithelial cells are polarized and thus have apical surfaces, which face the lumen, and 
basolateral surfaces, which contact the surrounding epithelial cells.  Many viruses have 
been shown to release progeny preferentially from one of these surfaces, including 
hepatitis A (Blank et al., 2000), measles virus (Blau and Compans, 1995), SV40 (Clayson 
et al., 1989), and Epstein-Barr virus, for which preferential basolateral release has been 
suggested to favor viral dissemination (Chodosh et al., 2000).  Rearranged strains may 
somehow be defective for viral egress at the apical surface but efficient at release from 
the basolateral surfaces, leading to dissemination into the blood.  In contrast, archetype 
strains may either mediate apical release preferentially from bladder epithelial cells and 
basolateral release from kidney epithelial cells, or perhaps have no preference for release.  
NCCR rearrangements could affect viral release by regulating replication kinetics, as 
described above.  Alternatively, rearrangements could result in differential regulation of 
agnoprotein expression; very little known about this protein, but it is suggested to be 
involved in virus maturation and release (Rinaldo et al., 1998).  
 
Ultimately, what are the factors that drive BKV reactivation in kidney transplant 
patients?  Currently, the list of potential risk factors for PVN includes older age, male 
gender, seropositivity of the donor, seronegativity of the recipient, specific 
immunosuppressive drugs, HLA mismatches, lack of the HLA-C7 allele in the donor or 
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recipient, acute rejection episodes prior to development of PVN, and low numbers of 
BKV-specific IFN-γ-producing T cells (Comoli et al., 2006; Egli et al., 2007).  
Immunosuppression regimens target lymphocytes, the major IFN-γ-producing cells, and 
prevent the activation and proliferation of these cells.  In Chapter II, we describe the 
inhibitory effect of IFN-γ on BKV replication.  A reduction in levels of this cytokine is 
likely a key factor that allows BKV reactivation.  In Chapter IV, we discuss future 
research plans to examine the specific factors involved in this regulation.  Transcription 
factor binding site prediction programs were of limited help in identifying potential 
responsive elements since IFN-γ-mediated inhibition of viral replication was strongest at 
late stages of infection, when the effects of IFN-γ signaling are robust and widespread, as 
a result of the activation and induction of many signaling components.  
While IFN-γ is a well-known antiviral cytokine, it is not frequently shown to have 
direct inhibitory activities on viral gene expression.  It is far more common for the type I 
interferon signaling pathway to mediate direct effects on viral replication, while IFN-γ 
signaling typically regulates the cellular immune response and activates cytotoxic T 
lymphocytes to kill virus-infected cells.  In our studies, IFN-α did not significantly affect 
BKV gene expression, suggesting that the virus is able to somehow avoid effectors of the 
type I pathway.  It is possible that transcription factors induced or activated by IFN-α/β 
signaling may be unable to regulate the BKV promoter due to a lack of the appropriate 
binding sites.  Alternatively, expression of an early viral protein, likely TAg based on 
similar findings for SV40 and Py (Swaminathan et al., 1996; Weihua et al., 1998), may 
block the IFN-α/β signaling pathway.  This explanation correlates with our observations 
that BKV infection does not activate any innate immune response in kidney epithelial 
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cells (J. Abend, J. Low, and M. Imperiale, unpublished data), and may also partially 
explain how BKV establishes persistence.   
We hypothesize that a key factor mediating reactivation is intense 
immunosuppresion of transplant patients.  The immunosuppressive regimen during the 
first year post-renal transplant is typically at higher doses than during later years post-
transplant.  Thus, it is possible that patients receive more immunosuppressant than is 
necessary to maintain the balance between preventing graft rejection and controlling viral 
reactivation.  In addition, there may be a subset of transplant patients that naturally have 
lower levels of cytokine production, and therefore would be more sensitive to 
immunosuppression.  Pravica et al. (1999) identified a polymorphism in the IFN-γ 
promoter that results in higher levels of IFN-γ production.  The polymorphism relates to 
the number of consecutive CA repeats, and the allele (12 CA repeats, designated allele 2) 
confers high production of IFN-γ in either homozygous or heterozygous individuals.  
Allele 2 is more frequent than any other allele, with 75% of the population having at least 
one copy (Pravica et al., 1999).  Thus, 25% of the population is negative for allele 2 and 
consequently has approximately two-fold lower levels of IFN-γ production, based on 
stimulation of PBMCs in vitro.  While this may not sound impressive, the effect in vivo 
and in the presence of immunosuppressive drugs may be more dramatic.  The frequency 
of low IFN-γ producers seems to roughly correlate with the frequency of PVN and HC: if 
25% of the transplant population is negative for allele 2, then it is reasonable to expect 
about half of these patients (10%) have another risk factor, such as age gender or donor 
seropositivity, and develop PVN.  
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In addition to polymorphisms that alter IFN-γ production, there are also 
polymorphisms that determine production levels of other relevant cytokines, for example, 
TGF-β (Grainger et al., 1999).  The IL-12 gene has a single nucleotide polymorphism 
that reduces the production of the p40 subunit of IL-12 (Stanilova and Miteva, 2005), and 
has recently been reported as a risk factor for human cytomegalovirus infection after 
kidney transplantation (Hoffmann et al., 2008).  IL-18 also has promoter polymorphisms 
that confer levels of expression (Giedraitis et al., 2001) and are implicated in disease 
outcome.  IL-12 and IL-18 (also known as the IFN-γ-inducing factor) are the major 
activators of IFN-γ production, and can act alone or in synergy.  Polymorphisms that 
confer low levels of expression of these cytokines could be associated with a higher risk 
of BKV reactivation.  It would be interesting and useful to determine if there is a 
correlation between these and other polymorphisms, and progression to HC or PVN.  
Patients could easily be screened for such polymorphisms prior to transplantation to 
determine if there is a high risk for reactivation.  In this situation, the immunosuppressive 
regimens could be adjusted and monitored.  
Although immunosuppression is important, the infrequency of BKV-associated 
disease in non-renal solid organ transplant recipients and patients with AIDS indicates 
that there are other conditions required for reactivation.  One such kidney-specific risk 
factor could be damage to the graft as a result of ischemia and reperfusion during 
transplantation.  Ischemia/reperfusion events may activate factors within BKV-infected 
cells that could promote viral reactivation, and since the kidney is the major site of BKV 




Based on the discussions in this chapter, a proposed model for the replication of 
archetype virus (left) and the factors that determine the prevalence of rearranged virus in 
the blood (right) is depicted in Figure 5.1.  First, the archetype virus establishes a 
persistent infection in kidney epithelial cells but is only able to express very low levels of 
TAg that do not support replication.  Random rearrangements produce a viral genome 
that has a highly active early region promoter but is defective for late gene expression, 
either by disruption of the coding region or an essential element of the late region 
promoter.  The resulting high levels of TAg then promote replication of archetype virus 
without producing rearranged virus.  The second part of this figure shows archetype virus 
release by a cell-mediated egress pathway, which leaves the infected cell intact.  The 
slower kinetics of archetype replication in healthy individuals may promote the use of 
this pathway, and egress may be directed to the apical side of the epithelial cell resulting 
in preferential release in urine.  The faster, more robust replication of rearranged strains 
may prevent utilization of this pathway, and instead result in a viral lytic burst.  
Destruction of the infected cell may promote spread to surrounding cells, in particular 
vascular endothelium, resulting in a preference for the release of rearranged strains into 
the bloodstream.  It is likely that archetype strains also cause cell lysis under certain 
conditions of robust replication, as these viruses are found both in blood and urine.   
In conclusion, this dissertation has provided an overview of BKV biology and 
pathogenesis, and a description of our findings on cytokine-mediated regulation of viral 
gene expression and replication.  We have also shown preliminary data on the mechanism 
of IFN-γ-mediated regulation and the replication of archetype strains in culture, and 
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proposed further studies.  Finally, we discussed the major questions in the field of BKV 
reactivation in transplant patients.  In the absence of effective antiviral therapies for 
BKV, a better understanding of persistence and factors that drive reactivation will 









Figure 5.1.  Proposed model for replication of archetype virus and factors that 
determine the prevalence of rearranged virus in the blood.  Replication of archetype 
virus (left): archetype virus persistence is established in a cell (genomes shown by yellow 
circles).  Weak TAg expression (thin arrow) does not support replication, however, 
random rearrangements produce a viral genome (purple circle) that has robust early 
promoter activity but is unable to produce VP1 and thus unable to propagate.  The high 
levels of TAg (thick purple arrow) are utilized by the archetype virus to facilitate 
replication.  Virus release pathways (right): archetype virus utilizes a cell-mediated 
egress pathway for progeny release, leaving the infected cell intact.  Rearranged virus 
(genomes shown by green circles), replicates robustly and overwhelms the cell with 
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